Most-cited articles · 2022

The 100 most-cited articles in Neurology, 2022

Ranked by OpenAlex citation count on 29 October 2026, out of 3,436 eligible articles Neurology published in 2022. Ranks are frozen; this page will not change. Number one, with 387 citations: Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.

Cohort
3,436 articles
Listed
Top 100 (2.9%)
Open access
82 of 100
Snapshot
2026-10-29

The most-cited articles published in Neurology in 2022 cluster around several themes. Neurodegenerative disease dominates the top of the list, with studies of glymphatic function and amyloid deposition in Alzheimer disease and mild cognitive impairment, gut microbiota and short-chain fatty acids in Parkinson disease, and plasma and CSF biomarkers for these conditions. The single most-cited paper is Kamagata and colleagues' study of MRI indices of the glymphatic system and their association with amyloid deposition and cognition, with 387 citations. Other prominent themes include social and lifestyle factors in dementia risk, such as social isolation, loneliness, leisure activities, and ultraprocessed food consumption, and the epidemiology, burden, and treatment of multiple sclerosis.

The list offers a view of the work that drew the most citation attention in the journal that year. Readers can use it to identify recurring research directions, compare citation counts across topics, and locate individual articles by title and author.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.1%

    Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease

    Koji Kamagata, Christina Andica, Kaito Takabayashi, Yuya Saito, Toshiaki Taoka and 13 more

    387 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000201300OpenAlex

    Show abstract

    Background and Objectives The glymphatic system is a whole-brain perivascular network, which promotes CSF/interstitial fluid exchange. Alterations to this system may play a pivotal role in amyloid β (Aβ) accumulation. However, its involvement in Alzheimer disease (AD) pathogenesis is not fully understood. Here, we investigated the changes in noninvasive MRI measurements related to the perivascular network in patients with mild cognitive impairment (MCI) and AD. Additionally, we explored the associations of MRI measures with neuropsychological score, PET standardized uptake value ratio (SUVR), and Aβ deposition. Methods MRI measures, including perivascular space (PVS) volume fraction (PVSVF), fractional volume of free water in white matter (FW-WM), and index of diffusivity along the perivascular space (ALPS index) of patients with MCI, those with AD, and healthy controls from the Alzheimer9s Disease Neuroimaging Initiative database were compared. MRI measures were also correlated with the levels of CSF biomarkers, PET SUVR, and cognitive score in the combined subcohort of patients…

  2. 2
    top 0.1%

    Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease

    Szu-Ju Chen, Chieh-Chang Chen, Hsin-Yu Liao, Ya-Ting Lin, Yu‐Wei Wu and 4 more

    268 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000013225OpenAlex

    Show abstract

    Background and Objectives Short-chain fatty acids (SCFAs) are gut microbial metabolites that promote the disease process in a rodent model of Parkinson disease (PD), but fecal levels of SCFAs in patients with PD are reduced. Simultaneous assessments of fecal and plasma SCFA levels, and their interrelationships with the PD disease process, are scarce. We aimed to compare fecal and plasma levels of different SCFA subtypes in patients with PD and healthy controls to delineate their interrelations and link to gut microbiota changes and clinical severity of PD. Methods A cohort of 96 patients with PD and 85 controls were recruited from National Taiwan University Hospital. Fecal and plasma concentrations of SCFAs were measured using chromatography and mass spectrometry. Gut microbiota was analyzed using metagenomic shotgun sequencing. Body mass index and medical comorbidities were evaluated and dietary information was obtained using a food frequency questionnaire. To assess motor and cognitive impairment, we used the Movement Disorder Society–Unified Parkinson9s Disease Rating Scale…

  3. 3
    top 0.1%

    Associations of Social Isolation and Loneliness With Later Dementia

    Chun Shen, Edmund T. Rolls, Wei Cheng, Jujiao Kang, Guiying Dong and 4 more

    255 citationsdoi:10.1212/wnl.0000000000200583OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: To investigate the independent associations of social isolation and loneliness with incident dementia and to explore the potential neurobiological mechanisms. METHODS: genotype, diabetes, cancer, cardiovascular disease, and other), cognitive (speed of processing and visual memory), behavioral (current smoker, alcohol intake, and physical activity), and psychological (social isolation or loneliness, depressive symptoms, and neuroticism) factors measured at baseline were adjusted. Then, voxel-wise brainwide association analyses were used to identify gray matter volumes (GMVs) associated with social isolation and with loneliness. Partial least squares regression was performed to test the spatial correlation of GMV differences and gene expression using the Allen Human Brain Atlas. RESULTS: We included 462,619 participants (mean age at baseline 57.0 years [SD 8.1]). With a mean follow-up of 11.7 years (SD 1.7), 4,998 developed all-cause dementia. Social isolation was associated with a 1.26-fold increased risk of dementia (95% CI, 1.15-1.37) independently of…

  4. 4
    top 0.2%

    The Economic Burden of Multiple Sclerosis in the United States

    Bruce Bebo, Inna Cintina, Nicholas LaRocca, Leslie Ritter, Bari Talente and 4 more

    211 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200150OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: A recent report estimated that approximately 1 million adults were living with multiple sclerosis (MS) in the United States. Although MS is rarely the direct cause of death, its debilitating effects on normal body functions can result in considerable disruption to daily living and life roles including work, physical independence, mobility, social interaction, and participation in leisure activities. This study estimated the total economic burden of MS in the United States in 2019. METHODS: This study used a prevalence-based approach to estimate the national economic burden of MS. Claims from 3 sources (Medicare Current Beneficiary Survey, Medicare Standard Analytical File, and Optum de-identified Normative Health Information System) were used to obtain direct costs and a survey was developed to collect indirect costs (e.g., labor market productivity losses, costs of paid and unpaid caregivers, home modification) from 946 patients with MS (PwMS). Direct medical costs reflected the difference in the total average annual amount paid for PwMS vs matched…

  5. 5
    top 0.2%

    Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease

    Kazuto Tsukita, Haruhi Sakamaki-Tsukita, Ryosuke Takahashi

    202 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000013218OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Owing to the lack of long-term observations or comprehensive adjustment for confounding factors, reliable conclusions regarding long-term effects of exercise and regular physical activity in Parkinson disease (PD) have yet to be drawn. Here, using data from the Parkinson's Progression Markers Initiative study that includes longitudinal and comprehensive evaluations of many clinical parameters, we examined the long-term effects of regular physical activity and exercise habits on the course of PD. METHODS: In this retrospective, observational cohort study, we primarily used the multivariate linear mixed-effects models to analyze the interaction effects of their regular physical activity and moderate to vigorous exercise levels, measured with the Physical Activity Scale for the Elderly questionnaire, on the progression of clinical parameters, after adjusting for age, sex, levodopa equivalent dose, and disease duration. We also calculated bootstrapping 95% confidence intervals (CIs) and conducted sensitivity analyses using the multiple imputation method and…

  6. 6
    top 0.2%

    α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies

    Giovanni Bellomo, Chiara Maria Giulia De Luca, Federico Paolini Paoletti, Lorenzo Gaetani, Fabio Moda and 1 more

    160 citationsdoi:10.1212/wnl.0000000000200878OpenAlex

    Show abstract

    Parkinson disease (PD) is the second most common neurodegenerative disease, and the most common synucleinopathy, as alpha-synuclein (α-syn), a prion-like protein, plays an important pathophysiologic role in its onset and progression. Although neuropathologic changes begin many years before the onset of motor manifestations, diagnosis still relies on the identification of the motor symptoms, which hinders to formulate an early diagnosis. Because α-syn misfolding and aggregation precede clinical manifestations, the possibility to identify these phenomena in patients with PD would allow us to recognize the disease at the earliest, premotor phases, as a consequence of the transition from a clinical to a molecular diagnosis. Seed amplification assays (SAAs) are a group of techniques that currently support the diagnosis of prion subacute encephalopathies, namely Creutzfeldt-Jakob disease. These techniques enable the detection of minimal amounts of prions in CSF and other matrices of affected patients. Recently, SAAs have been successfully applied to detect misfolded alpha-synuclein…

  7. 7
    top 0.3%

    International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy

    Marc Engelen, Wouter J. C. van Ballegoij, Eric James Mallack, Keith P. van Haren, Wolfgang Köhler and 23 more

    156 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201374OpenAlex

    Show abstract

    gene cause adrenoleukodystrophy (ALD), a progressive metabolic disorder characterized by 3 core clinical syndromes: a slowly progressive myeloneuropathy, a rapidly progressive inflammatory leukodystrophy (cerebral ALD), and primary adrenal insufficiency. These syndromes are not present in all individuals and are not related to genotype. Cerebral ALD and adrenal insufficiency require early detection and intervention and warrant clinical surveillance because of variable penetrance and age at onset. Newborn screening has increased the number of presymptomatic individuals under observation, but clinical surveillance protocols vary. We used a consensus-based modified Delphi approach among 28 international ALD experts to develop best-practice recommendations for diagnosis, clinical surveillance, and treatment of patients with ALD. We identified 39 discrete areas of consensus. Regular monitoring to detect the onset of adrenal failure and conversion to cerebral ALD is recommended in all male patients. Hematopoietic cell transplant (HCT) is the treatment of choice for cerebral ALD. This…

  8. 8
    top 0.3%

    Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia

    Karen Sugden, Avshalom Caspi, Maxwell L. Elliott, Kyle J. Bourassa, Kartik Chamarti and 11 more

    145 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200898OpenAlex

    Show abstract

    Background and Objectives DNA methylation algorithms are increasingly used to estimate biological aging; however, how these proposed measures of whole-organism biological aging relate to aging in the brain is not known. We used data from the Alzheimer9s Disease Neuroimaging Initiative (ADNI) and the Framingham Heart Study (FHS) Offspring Cohort to test the association between blood-based DNA methylation measures of biological aging and cognitive impairment and dementia in older adults. Methods We tested 3 “generations” of DNA methylation age algorithms (first generation: Horvath and Hannum clocks; second generation: PhenoAge and GrimAge; and third generation: DunedinPACE, Dunedin Pace of Aging Calculated from the Epigenome) against the following measures of cognitive impairment in ADNI: clinical diagnosis of dementia and mild cognitive impairment, scores on Alzheimer disease (AD) / Alzheimer disease and related dementias (ADRD) screening tests (Alzheimer9s Disease Assessment Scale, Mini-Mental State Examination, and Montreal Cognitive Assessment), and scores on cognitive tests (Rey…

  9. 9
    top 0.3%

    Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice

    Shreya Louis, Alise K. Carlson, Abhilash Suresh, Joshua Rim, MaryAnn Mays and 2 more

    144 citationsOpen accessdoi:10.1212/wnl.0000000000201630OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Although the international community collectively seeks to reduce global temperature rise to less than 1.5°C before 2100, irreversible environmental changes have already occurred, and as the planet warms, these changes will continue to occur. As we witness the effects of a warming planet on human health, it is imperative that neurologists anticipate how the epidemiology and incidence of neurologic disease may change. In this review, we organized our analysis around 3 key themes related to climate change and neurologic health: extreme weather events and temperature fluctuations, emerging neuroinfectious diseases, and pollutant impacts. Across each of these themes, we appraised and reviewed recent literature relevant to neurologic disease and practice. METHODS: Studies were identified using search terms relating to climate change, pollutants, and neurologic disease in PubMed, OVID MEDLINE, EMBASE, PsycInfo, and gray literature. Studies published between 1990 and 2022 were included if they pertained to human incidence or prevalence of disease, were in…

  10. 10
    top 0.3%

    Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light

    Suzanne E. Schindler, Thomas K. Karikari, Nicholas James Ashton, Rachel L. Henson, Kevin E. Yarasheski and 16 more

    142 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200358OpenAlex

    Show abstract

    Background and Objectives To evaluate whether plasma biomarkers of amyloid (Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light chain [NfL]) detect brain amyloidosis consistently across racial groups. Methods Individuals enrolled in studies of memory and aging who self-identified as African American (AA) were matched 1:1 to self-identified non-Hispanic White (NHW) individuals by age, APOE ε4 carrier status, and cognitive status. Each participant underwent blood and CSF collection, and amyloid PET was performed in 103 participants (68%). Plasma Aβ42/Aβ40 was measured by a high-performance immunoprecipitation–mass spectrometry assay. Plasma p-tau181, p-tau231, and NfL were measured by Simoa immunoassays. CSF Aβ42/Aβ40 and amyloid PET status were used as primary and secondary reference standards of brain amyloidosis, respectively. Results There were 76 matched pairs of AA and NHW participants (n = 152 total). For both AA and NHW groups, the median age was 68.4 years, 42% were APOE ε4 carriers, and 91% were cognitively normal. AA were less likely than…

  11. 11
    top 0.4%

    Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration

    Niklas Mattsson, Lea T. Grinberg, Adam L. Boxer, Rik Ossenkoppele, Magnus Jonsson and 16 more

    134 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200040OpenAlex

    Show abstract

    Background and Objectives To determine how fully automated Elecsys CSF immunoassays for β-amyloid (Aβ) and tau biomarkers and an ultrasensitive Simoa assay for neurofilament light chain (NFL) correlate with neuropathologic changes of Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). Methods We studied 101 patients with antemortem CSF and neuropathology data. CSF samples were collected a mean of 2.9 years before death (range 0.2–7.5 years). CSF was analyzed for Aβ 40 , Aβ 42 , total tau (T-tau), tau phosphorylated at amino acid residue 181 (P-tau), P-tau/Aβ 42 and Aβ 42 /Aβ 40 ratios, and NFL. Neuropathology measures included Thal phases, Braak stages, Consortium to Establish a Registry for Alzheimer's Disease (CERAD) scores, AD neuropathologic change (ADNC), and primary and contributory pathologic diagnoses. Associations between CSF biomarkers and neuropathologic features were tested in regression models adjusted for age, sex, and time from sampling to death. Results CSF biomarkers were associated with neuropathologic measures of Aβ (Thal, CERAD score), tau (Braak…

  12. 12
    top 0.4%

    Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging

    Rosa Cortese, Ferrán Prados, Carmen Tur, Alessia Bianchi, Wallace J. Brownlee and 14 more

    131 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201465OpenAlex

    Show abstract

    Background and Objectives Relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination. Methods Adult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (London, United Kingdom) and the Walton Centre (Liverpool, United Kingdom) between 2014 and 2019. They underwent conventional and advanced brain, cord, and optic nerve MRI and optical coherence tomography (OCT). Results A total of 91 consecutive patients (31 RRMS, 30 APQ4-NMOSD, and 30 MOGAD) and 34 healthy controls were recruited. The most accurate measures differentiating RRMS from AQP4-NMOSD…

  13. 13
    top 0.4%

    Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms

    Alexander McGirr, Santhosh Nathan, Maryam Ghahremani, Sascha Gill, Eric Edward Smith and 1 more

    129 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200256OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Mild cognitive impairment (MCI) is an at-risk state for dementia; however, not all individuals with MCI transition to dementia, and some revert to normal cognition (NC). Here, we investigate whether mild behavioral impairment (MBI), the late-life onset of persistent neuropsychiatric symptoms (NPS), improves the prognostic specificity of MCI. METHODS: Participants with MCI from the National Alzheimer's Coordinating Center Uniform Data Set were included. NPS were operationalized with the Neuropsychiatric Inventory Questionnaire to identify participants without NPS and those with MBI (persistent, late-onset NPS). Individuals with late-onset NPS not meeting the MBI persistence criterion (NPS_NOT_MBI) were retained for secondary analyses. Progression to dementia, stable MCI, and reversion to NC after 3 years of follow-up were defined per National Institute on Aging-Alzheimer's Association and Petersen criteria. RESULTS: The primary sample consisted of 739 participants (NPS- n = 409 and MBI+ n = 330; 75.16 ± 8.6 years old, 40.5% female). After 3 years, 238…

  14. 14
    top 0.5%

    Global Burden of Ischemic Stroke in Young Adults in 204 Countries and Territories

    Ruijie Zhang, Huina Liu, Liyuan Pu, Tian Zhao, Shun Zhang and 2 more

    125 citationsdoi:10.1212/wnl.0000000000201467OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: To estimate the rates of incidence, death, and disability-adjusted life years (DALYs) of ischemic stroke in young adults aged 15-49 years and the relevant risk factors by sex, age group, and sociodemographic index (SDI) in 204 countries and territories. METHODS: Data from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2019 study were used. The estimated annual percentage changes (EAPCs) were calculated to evaluate the temporal trends from 1990 to 2019. We also estimated the risk factors contributing to DALYs resulting from ischemic stroke. RESULTS: From 1990 to 2019, the global age-standardized incidence (EAPC = -0.97), death (EAPC = -0.11), and DALYs rates (EAPC = -0.55) of ischemic stroke in young adults decreased. The largest increases in age-standardized incidence, death, and DALYs rates were observed in the low and low-middle SDI quintiles. At the regional level, North Africa and the Middle East and Southeast Asia showed the largest increases in the age-standardized incidence, death, and DALYs rates of ischemic stroke. The…

  15. 15
    top 0.5%

    Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline

    Joel Salinas, Alexa Beiser, Jasmeet K. Samra, Adrienne O’Donnell, Charles S DeCarli and 3 more

    125 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200039OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Loneliness is common, and its prevalence is rising. The relationship of loneliness with subsequent dementia and the early preclinical course of Alzheimer disease and related dementia (ADRD) remains unclear. Thus, the primary objective of this study was to determine the association of loneliness with 10-year all-cause dementia risk and early cognitive and neuroanatomic imaging markers of ADRD vulnerability. METHODS: This was a retrospective analysis of prospectively collected data from the population-based Framingham Study cohorts (September 9, 1948-December 31, 2018). Eligible participants had loneliness assessed and were dementia-free at baseline. Loneliness was recorded with the Center for Epidemiologic Studies Depression Scale, defined conservatively as feeling lonely ≥3 days in the past week. The main outcomes were incident dementia over a 10-year period, cognition, and MRI brain volumes and white matter injury. RESULTS: ε4 alleles had a 3-fold greater risk (adjusted hazard ratio 3.03, 95% CI, 1.63-5.62). Among 1,875 persons without dementia who met…

  16. 16
    top 0.5%

    Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease

    Paula Barreras, Eleni S. Vasileiou, Angeliki G. Filippatou, Kathryn C. Fitzgerald, Michael Levy and 5 more

    123 citationsOpen accessdoi:10.1212/wnl.0000000000201260OpenAlex

    Show abstract

    Background and Objectives Rituximab is used widely for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG–associated disease (MOGAD); however, data regarding the effectiveness and safety of long-term rituximab use in these conditions are limited. In this study, we sought to evaluate long-term clinical outcomes in patients with aquaporin-4 IgG–seropositive (AQP4-IgG+) NMOSD and MOGAD treated with rituximab. Methods We performed a retrospective chart review of patients with AQP4-IgG+ NMOSD or MOGAD followed at the Johns Hopkins Neuromyelitis Optica Clinic and included patients who had received at least 1 dose of rituximab. Results We identified 111 patients with NMOSD and 23 patients with MOGAD who fulfilled the inclusion criteria. The median duration of rituximab treatment for the patients with NMOSD was 3.7 years (range: 0.5–13.2 years) and for the patients with MOGAD was 2.1 years (range: 0.5–7.0 years). The annualized relapse rate (ARR) decreased after rituximab initiation in both NMOSD (median ARR: pretreatment…

  17. 17
    top 0.5%

    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence

    Annette Magdalene Langer-Gould, Edlin Grisell Gonzales, Jessica B. Smith, Bonnie H. Li, Lorene M. Nelson

    122 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200151OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The goal of this work was to determine whether the prevalence of multiple sclerosis (MS) varies by race and ethnicity. METHODS: code for MS between January 1, 2008 and December 31, 2010 were reviewed. MS prevalence and 95% CIs stratified by age, sex, and race and ethnicity among 2010 members were estimated with binomial regression. Age- and sex-standardized prevalence was estimated according to the 2010 US Census population. RESULTS: We identified 3,863 patients with MS. The average age of patients with prevalent MS was 51.7 years (SD 13.1 years), and 76.8% were women. The female preponderance was more pronounced among Black (81.2%) and Asian (83.6%) than White (76.3%) or Hispanic (74.5%) individuals with MS. Age- and sex-standardized MS prevalence per 100,000 was similarly high among Black (225.8, 95% CI 207.1-244.5) and White (237.7, 95% CI 228.2-247.2) and significantly lower among Hispanic (69.9, 95% CI 64.4-75.5) and Asian (22.6, 95% CI 17.1-28.1) persons. MS prevalence was highest between the ages of 35 and 64 years and declined after 65 years of age…

  18. 18
    top 0.6%

    Leisure Activities and the Risk of Dementia

    Sizhen Su, Le Shi, Yongbo Zheng, Yankun Sun, Xiaolin Huang and 7 more

    114 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200929OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Leisure activities are major components of modifiable and healthy lifestyles and are proposed to help prevent the development of dementia. This study aimed to assess the effects of different types of leisure activities, including cognitive, physical, and social activities, on the incidence of all-cause dementia (ACD), Alzheimer disease (AD), and vascular dementia (VD). METHODS: We performed a systematic review and meta-analysis of the Cochrane, PubMed, Embase, and Web of Science databases to identify longitudinal studies that examined associations between leisure activities and dementia. Relative risks (RRs) and 95% CIs were pooled using random-effects meta-analysis. Subgroup analyses were used to estimate potential effect modifiers. The study was registered with PROSPERO (CRD42019116857). RESULTS: A total of 38 longitudinal studies, with 2,154,818 participants at baseline, 74,700 ACD cases, 2,848 AD cases, and 1,423 VD cases during follow-up, were included in the meta-analysis. The subgroup analyses showed that physical (RR 0.83, 95% CI 0.78-0.88),…

  19. 19
    top 0.6%

    Association of Ultraprocessed Food Consumption With Risk of Dementia

    Huiping Li, Shu Li, Hongxi Yang, Yuan Zhang, Shunming Zhang and 6 more

    107 citationsdoi:10.1212/wnl.0000000000200871OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: There has been a growing body of evidence associating consumption of ultraprocessed foods (UPF) with adverse health outcomes including depression, cardiovascular disease, and all-cause mortality. However, whether UPF are associated with dementia is unknown. The authors investigated the associations between UPF and dementia incidence in the UK Biobank. METHODS: We included 72,083 participants (55 years or older) who were free from dementia at baseline and provided at least 2 times 24-hour dietary assessments from the UK Biobank study. Follow-up occurred through March 2021. UPF were defined according to the NOVA classification. Incident all-cause dementia comprising Alzheimer disease (AD) and vascular dementia was ascertained through electronic linkages to hospital and mortality records. Cox proportional hazards were used to estimate the association between the proportion (%) of UPF in the diet and the subsequent risk of dementia. In addition, substitution analysis was used to estimate the risk of dementia when substituting UPF with an equivalent proportion…

  20. 20
    top 0.6%

    Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory

    Tanya N. Turan, Osama O. Zaidat, Gary Gronseth, Marc I. Chimowitz, Antonio Culebras and 14 more

    102 citationsdoi:10.1212/wnl.0000000000200030OpenAlex

    Show abstract

    Background and Objectives To review treatments for reducing the risk of recurrent stroke or death in patients with symptomatic intracranial atherosclerotic arterial stenosis (sICAS). Methods The development of this practice advisory followed the process outlined in the American Academy of Neurology Clinical Practice Guideline Process Manual, 2011 Edition, as amended. The systematic review included studies through November 2020. Recommendations were based on evidence, related evidence, principles of care, and inferences. Major Recommendations Clinicians should recommend aspirin 325 mg/d for long-term prevention of stroke and death and should recommend adding clopidogrel 75 mg/d to aspirin for up to 90 days to further reduce stroke risk in patients with severe (70%–99%) sICAS who have low risk of hemorrhagic transformation. Clinicians should recommend high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol level <70 mg/dL, a long-term blood pressure target of <140/90 mm Hg, at least moderate physical activity, and treatment of other modifiable vascular risk…

  21. 21
    top 0.7%

    Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures

    Pavel Klein, Sami Aboumatar, Christian Brandt, Fang Dong, Gregory L. Krauss and 4 more

    101 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200792OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: To evaluate long-term efficacy (percent seizure frequency reduction and responder rates), safety, and tolerability of adjunctive cenobamate (CNB) in an open-label extension (OLE) of the randomized, double-blind, placebo-controlled study. METHODS: Patients (aged 18-70 years) with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications who completed the 18-week double-blind study (n = 360) could enter the OLE, where they underwent a 2-week blinded conversion to CNB (target dose, 300 mg/d; min/max, 50/400 mg/d). RESULTS: Three hundred fifty-five patients were included in the OLE safety population (265 originally randomized to CNB, 90 originally randomized to placebo), and 354 were included in the OLE modified intent-to-treat population. As of July 2019, 58.9% of patients (209/355) were continuing CNB treatment and 141 had discontinued, including 16.6% (59/355) because of lack of efficacy, 8.7% (31/355) because of withdrawal by patient, and 7.6% (27/355) because of adverse events. The median (range) duration of OLE exposure was 53.9…

  22. 22
    top 0.7%

    Association of Data-Driven White Matter Hyperintensity Spatial Signatures With Distinct Cerebral Small Vessel Disease Etiologies

    Chia‐Ling Phuah, Yasheng Chen, Jeremy F. Strain, Nirupama Yechoor, Osvaldo Laurido-Soto and 3 more

    99 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000201186OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Topographical distribution of white matter hyperintensities (WMH) are hypothesized to vary by cerebrovascular risk factors. We used an unbiased pattern discovery approach to identify distinct WMH spatial patterns and investigate their association with different WMH etiologies. METHODS: We performed a cross-sectional study on participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI) to identify spatially distinct WMH distribution patterns using voxel-based spectral clustering analysis of aligned WMH probability maps. We included all participants from the ADNI Grand Opportunity/ADNI 2 study with available baseline 2D-FLAIR MRI scans, without history of stroke or presence of infarction on imaging. We evaluated the associations of these WMH spatial patterns with vascular risk factors, amyloid-β PET, and imaging biomarkers of cerebral amyloid angiopathy (CAA), characterizing different forms of cerebral small vessel disease (CSVD) using multivariable regression. We also used linear regression models to investigate whether WMH spatial distribution…

  23. 23
    top 0.7%

    Relation Between Sex, Menopause, and White Matter Hyperintensities

    Valerie Lohner, Gökhan Pehlivan, Gerard Sanromà, Anne Miloschewski, Markus D. Schirmer and 3 more

    97 citationsOpen accessdoi:10.1212/wnl.0000000000200782OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Mounting evidence implies that there are sex differences in white matter hyperintensity (WMH) burden in older people. Questions remain regarding possible differences in WMH burden between men and women of younger age, sex-specific age trajectories and effects of (un)controlled hypertension, and the effect of menopause on WMH. Therefore, our aim was to investigate these sex differences and age dependencies in WMH load across the adult life span and to examine the effect of menopause. METHODS: -standardized) using linear regression models while adjusting for age, age-squared, and vascular risk factors. We checked for an age × sex and (un)controlled hypertension × sex interaction and stratified for menopausal status comparing men with premenopausal women (persons aged 59 years or younger), men with postmenopausal women (persons aged 45 years or older), and premenopausal with postmenopausal women (age range 45-59 years). RESULTS: Of 3,410 participants with a mean age of 54.3 years (SD = 13.7), 1,973 (57.9%) were women, of which 1,167 (59.1%) were…

  24. 24
    top 0.7%

    Spatial-Temporal Patterns of β-Amyloid Accumulation

    Lyduine Eisa Collij, Gemma Salvadó, Viktor Wottschel, Sophie E Mastenbroek, Pierre Schoenmakers and 12 more

    97 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200148OpenAlex

    Show abstract

    Background and Objectives β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data. Methods Amyloid-PET data of 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, and ADNI). Standardized uptake value ratios were calculated for 17 regions. We applied the SuStaIn algorithm to identify consistent subtypes in the pooled dataset based on the cross-validation information criterion and the most probable subtype/stage classification per scan. The effects of demographics and risk factors on subtype assignment were assessed using multinomial logistic regression. Results Participants were mostly cognitively unimpaired (n = 1890 [62.8%]), had a mean age of 68.72 (SD 9.1) years, 42.1% were APOE ε4 carriers, and 51.8% were female. A 1-subtype model recovered the traditional amyloid accumulation trajectory, but SuStaIn identified 3 optimal subtypes, referred to as frontal, parietal, and…

  25. 25
    top 0.8%

    Neuromodulation in 2035

    Timothy Denison, Martha J. Morrell

    97 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000013061OpenAlex

    Show abstract

    Neuromodulation devices are approved in the United States for the treatment of movement disorders, epilepsy, pain, and depression, and are used off-label for other neurologic indications. By 2035, advances in our understanding of neuroanatomical networks and in the mechanism of action of stimulation, coupled with developments in material science, miniaturization, energy storage, and delivery, will expand the use of neuromodulation devices. Neuromodulation approaches are flexible and modifiable. Stimulation can be targeted to a dysfunctional brain focus, region, or network, and can be delivered as a single treatment, continuously, according to a duty cycle, or in response to physiologic changes. Programming can be titrated and modified based on the clinical response or a physiologic biomarker. In addition to keeping pace with clinical and technological developments, neurologists in 2035 will need to navigate complex ethical and economic considerations to ensure access to neuromodulation technology for a rapidly expanding population of patients. This article provides an overview of…

  26. 26
    top 0.8%

    Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children

    Gemma Poke, James Stanley, Ingrid Eileen Scheffer, Lynette Grant Sadleir

    96 citationsOpen accessdoi:10.1212/wnl.0000000000206758OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: We aimed to determine the population-based cumulative incidence and prevalence of developmental and epileptic encephalopathies (DEEs) and intellectual disability and epilepsy (ID+E) in children. We analyzed the cumulative incidence of specific epilepsy syndromes. METHODS: Children younger than 16 years with a DEE or ID+E were ascertained using EEG records from 2000 to 2016 in the Wellington region of New Zealand. Epilepsy syndromes were diagnosed on medical record and EEG review. Point prevalence and cumulative incidence for children with epilepsy and developmental impairment, DEE and ID+E were calculated. Cumulative incidence for each epilepsy syndrome was calculated. RESULTS: The cohort comprised 235 children (58% male) with developmental impairment and epilepsy, including 152 (65%) with DEE and 83 (35%) with ID+E. The median age of seizure onset was 15.4 months (range day 1-15 years). The median follow-up from seizure onset was 7.9 years (range 0-18.2 years). Point prevalence for the broad group of children with epilepsy and developmental impairment was…

  27. 27
    top 0.8%

    Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort

    Vincent Planche, Vincent Bouteloup, Isabelle Pellegrin, Jean‐François Mangin, Bruno Dubois and 18 more

    93 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000201479OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVE: Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET biomarkers and effectively discriminate AD from other neurodegenerative diseases. Our aim was to test their utility in clinical practice, from a multicentric unselected prospective cohort where patients presented with a large spectrum of cognitive deficits or complaints. METHODS: The MEMENTO cohort enrolled 2,323 outpatients with subjective cognitive complaint (SCC) or mild cognitive impairment (MCI) consulting in 26 French memory clinics. Participants had neuropsychological assessments, MRI, and blood sampling at baseline. CSF sampling and amyloid PET were optional. Baseline blood Aβ42/40 ratio, total tau, p181-tau, and neurofilament light chain (NfL) were measured using a Simoa HD-X analyzer. An expert committee validated incident dementia cases during a 5-year follow-up period. RESULTS: < 0.0001). Blood p181-tau was the best blood biomarker to identify amyloid-PET positivity (area under the curve = 0.74 [95% CI = 0.69; 0.79]). Higher blood and CSF…

  28. 28
    top 0.9%

    Longitudinal Changes of White Matter Hyperintensities in Sporadic Small Vessel Disease

    Angela C.C. Jochems, Carmen Arteaga, Francesca M. Chappell, Tuula E. Ritakari, Monique Hooley and 3 more

    93 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201205OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: White matter hyperintensities (WMHs) are frequent imaging features of small vessel disease (SVD) and related to poor clinical outcomes. WMH progression over time is well described, but regression was also noted recently, although the frequency and associated factors are unknown. This systematic review and meta-analysis aims to assess longitudinal intraindividual WMH volume changes in sporadic SVD. METHODS: We searched EMBASE and MEDLINE for articles up to 28 January 2022 on WMH volume changes using MRI on ≥2 time points in adults with sporadic SVD. We classified populations (healthy/community-dwelling, stroke, cognitive, other vascular risk factors, and depression) based on study characteristics. We performed random-effects meta-analyses with Knapp-Hartung adjustment to determine mean WMH volume change (change in milliliters, percentage of intracranial volume [%ICV], or milliliters per year), 95% CI, and prediction intervals (PIs, limits of increase and decrease) using unadjusted data. Risk of bias assessment tool for nonrandomized studies was used to…

  29. 29
    top 0.9%

    Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia

    Bryn Farnsworth, Maria Josefsson, Anders Wåhlin, Lars H Nyberg, Nina Karalija

    92 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200255OpenAlex

    Show abstract

    Background and Objectives Cardiovascular risk factors have a recently established association with cognitive decline and dementia, yet most studies examine this association through cross-sectional data, precluding an understanding of the longitudinal dynamics of such risk. The current study aims to explore how the ongoing trajectory of cardiovascular risk affects subsequent dementia and memory decline risk. We hypothesize that an accelerated, long-term accumulation of cardiovascular risk, as determined by the Framingham Risk Score (FRS), will be more detrimental to cognitive and dementia state outcomes than a stable cardiovascular risk. Methods We assessed an initially healthy, community-dwelling sample recruited from the prospective cohort Betula study. Cardiovascular disease risk, as assessed by the FRS, episodic memory performance, and dementia status were measured at each 5-year time point (T) across 20 to 25 years. Analysis was performed with bayesian additive regression tree, a semiparametric machine-learning method, applied herein as a multistate survival analysis method.…

  30. 30
    top 0.9%

    An International Perspective on Preceding Infections in Guillain-Barré Syndrome

    Sonja Emily Leonhard, Annemiek A. van der Eijk, Henning Andersen, Giovanni Antonini, Samuel Arends and 25 more

    91 citationsOpen access (OTHER-OA)doi:10.1212/wnl.0000000000200885OpenAlex

    Show abstract

    Background and Objectives Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale. Methods We analyzed the first 1,000 patients included in the International GBS Outcome Study with available biosamples (n = 768) for the presence of a recent infection with Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus. Results Serologic evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%), and Epstein-Barr virus in 7 (1%) patients. Evidence of more than 1 recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing…

  31. 31
    top 1%

    Air Pollution and Incidence of Dementia

    Ehsan Abolhasani, Vladimir Hachinski, Nargess Ghazaleh, Mahmoud Reza Azarpazhooh, Naghmeh Mokhber and 1 more

    88 citationsdoi:10.1212/wnl.0000000000201419OpenAlex

    Show abstract

    Background and Objectives Studies of association between air pollution and incidence of dementia have shown discrepant results. The aim of this study was to evaluate the association between air pollution and dementia. Methods In this systematic review and meta-analysis, PubMed, MEDLINE, EMBASE, PsycINFO, Scopus, and Web of Science were searched and updated in August 2021. Population-based cohort studies that reported on hazard ratio (HR) of dementia in association with exposure to fine particulate matter (PM2·5), nitrogen oxides (NOX), nitrogen dioxide (NO2), or ozone (O3) in those aged >40 years were included. Data were extracted by 2 independent investigators. The main outcome was the pooled HR for dementia per increment of pollutant, calculated using a random-effects model. Results were reported in accordance with PRISMA guidelines. The protocol was registered in PROSPERO (registration number: CRD42020219036). Results A total of 20 studies were included in the systematic review, and 17 provided data for the meta-analysis. The total included population was 91,391,296, with…

  32. 32
    top 1%

    Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF

    Sara Carta, Álvaro Cobo‐Calvo, Thaís Armangué, Albert Saiz, Christian Lechner and 25 more

    86 citationsOpen accessdoi:10.1212/wnl.0000000000201662OpenAlex

    Show abstract

    Background and Objectives: Although the diagnosis of myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) is based on serum MOG antibodies (MOG-Abs) positivity, patients with coexisting or restricted MOG-Abs in the CSF have been reported. The aim of this study is to characterize the relevance of CSF MOG-Abs positivity in clinical practice. Methods: Eleven medical centres retrospectively collected clinical and laboratory data of adult and pediatric patients with suspected inflammatory CNS disease and MOG-Abs positivity in serum and/or CSF, using live cell-based assays. Comparisons were performed using parametric or non-parametric tests, as appropriate. Potential factors of unfavourable outcomes were explored by Cox proportional hazard models and logistic regression. Results: The cohort included 255 patients: 139 (55%) females and 132 (52%) children (i.e. <18 year-old). Among them, 145 patients (56.8%) had MOG-Abs in both serum and CSF (MOG-Abs seropositive and CSF positive), 79 (31%) only in serum (MOG-Abs seropositive and CSF negative), and 31 (12%) only in CSF…

  33. 33
    top 1%

    Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages

    Emma Borland, Chris J. Edgar, Erik Stomrud, Nicholas C. Cullen, Oskar Hansson and 1 more

    83 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200817OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Identifying a clinically meaningful change in cognitive test score is essential when using cognition as an outcome in clinical trials. This is especially relevant because clinical trials increasingly feature novel composites of cognitive tests. Our primary objective was to establish minimal clinically important differences (MCIDs) for commonly used cognitive tests, using anchor-based and distribution-based methods, and our secondary objective was to investigate a composite cognitive measure that best predicts a minimal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB). METHODS: From the Swedish BioFINDER cohort study, we consecutively included cognitively unimpaired (CU) individuals with and without subjective or mild cognitive impairment (MCI). We calculated MCIDs associated with a change of ≥0.5 or ≥1.0 on CDR-SB for Mini-Mental State Examination (MMSE), ADAS-Cog delayed recall 10-word list, Stroop, Letter S Fluency, Animal Fluency, Symbol Digit Modalities Test (SDMT) and Trailmaking Test (TMT) A and B, and triangulated MCIDs for clinical use…

  34. 34
    top 1%

    Nonalcoholic Fatty Liver Disease and Risk of Dementia

    Ying Shang, Linnea Widman, Hannes Hagström

    83 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200853OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) and dementia share common risk factors including metabolic disorders. However, whether NAFLD is associated with dementia risk is unclear. We investigated the association between NAFLD and dementia risk as well as the role of cardiovascular complications including heart disease and stroke. METHODS: In this population-based matched cohort study, we identified all Swedish patients aged 65 years or older with NAFLD identified from the National Patient Register (NPR) between 1987 and 2016. These were matched with up to 10 reference individuals from the general population on age, sex, and municipality at the year of diagnosis. Incident dementia diagnosis was derived from the NPR or the Cause of Death Register until 2016. Adjusted hazard ratios (aHRs) and 95% CIs were estimated with Cox regression models. RESULTS: = 0.07). Comorbid NAFLD and either heart disease (aHR 1.50 95% 1.08-2.05) or stroke (aHR 2.60 95% CI 1.95-3.47) conferred a greater risk of dementia. DISCUSSION: NAFLD had a modest association with increased…

  35. 35
    top 1.1%

    Cognitive Outcome 1 Year After Mild Traumatic Brain Injury

    Andrea L.C. Schneider, John Russell Huie, W. John Boscardin, Lindsay D. Nelson, Jason K. Barber and 25 more

    82 citationsOpen accessdoi:10.1212/wnl.0000000000200041OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The objectives of this study were to develop and establish concurrent validity of a clinically relevant definition of poor cognitive outcome 1 year after mild traumatic brain injury (mTBI), to compare baseline characteristics across cognitive outcome groups, and to determine whether poor 1-year cognitive outcome can be predicted by routinely available baseline clinical variables. METHODS: Prospective cohort study included 656 participants ≥17 years of age presenting to level 1 trauma centers within 24 hours of mTBI (Glasgow Coma Scale score 13-15) and 156 demographically similar healthy controls enrolled in the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study. Poor 1-year cognitive outcome was defined as cognitive impairment (below the ninth percentile of normative data on ≥2 cognitive tests), cognitive decline (change score [1-year score minus best 2-week or 6-month score] exceeding the 90% reliable change index on ≥2 cognitive tests), or both. Associations of poor 1-year cognitive outcome with 1-year neurobehavioral outcomes were…

  36. 36
    top 1.1%

    Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis

    Linda G. Snetselaar, Joshua J. Cheek, Sara Shuger Fox, Heather S. Healy, Marin Leigh Schweizer and 3 more

    81 citationsOpen accessdoi:10.1212/wnl.0000000000201371OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVE: Emerging evidence suggests a role for diet in multiple sclerosis (MS) care; however, owing to methodological issues and heterogeneity of dietary interventions in preliminary trials, the current state of evidence does not support dietary recommendations for MS. The objective of this study was to assess the efficacy of different dietary approaches on MS-related fatigue and quality of life (QoL) through a systematic review of the literature and network meta-analysis (NMA). METHODS: Electronic database searches were performed in May 2021. Inclusion criteria were (1) randomized trial with a dietary intervention, (2) adults with definitive MS based on McDonald criteria, (3) patient-reported outcomes for fatigue and/or QoL, and (4) minimum intervention period of 4 weeks. For each outcome, standardized mean differences (SMDs) were calculated and included in random effects NMA to determine the pooled effect of each dietary intervention relative to each of the other dietary interventions. The protocol was registered at PROSPERO (CRD42021262648). RESULTS: Twelve…

  37. 37
    top 1.1%

    Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up

    Teemu Kipinoinen, Sini Toppala, Juha O. Rinne, Matti H. Viitanen, Antti Jula and 1 more

    81 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201116OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cognitive performance after a 10-year follow-up. We hypothesized that low-grade inflammation, estimated by interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity CRP (hs-CRP), is a predictor of cognitive decline in the general population. METHODS: genotype, type 2 diabetes, hypertension, hypercholesterolemia, body mass index, depressive symptoms, smoking, and baseline cognition. RESULTS: = 0.008). Baseline TNF-α did not predict cognitive decline, and hs-CRP did not predict cognitive performance or decline after 10-years. DISCUSSION: Our results suggest that low-grade inflammation in midlife is an independent risk factor for poorer cognitive performance later in life. Of the studied markers, IL-6 and TNF-α seem to be stronger predictors for…

  38. 38
    top 1.2%

    Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis

    Alberto Calvi, Ferrán Prados, Carmen Tur, Declan Chard, Jonathan Stutters and 11 more

    81 citationsdoi:10.1212/wnl.0000000000200144OpenAlex

    Show abstract

    Background and Objective To explore the relationship between slowly expanding lesions (SELs) on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods We retrospectively studied 345 patients with SPMS enrolled in the MS-SMART trial. They underwent brain MRI at baseline and at 24 and 96 weeks. Definite SELs were defined as concentrically expanding T2 lesions, as assessed by nonlinear deformation of volumetric T1-weighted images. Associations of SEL volumes with other MRI metrics and disability were assessed through Pearson correlations and regression analyses. Results Averaged across patients, 29% of T2 lesions were classified as being definite SELs. A greater volume of definite SELs correlated with a higher total baseline T2 lesion volume (r = 0.55, p < 0.001) and percentage brain volume reduction (r = −0.26, p < 0.001), a higher number of new persisting T1 black holes (r = 0.19, p < 0.001), and, in a subset of 106 patients, with a greater reduction in magnetization transfer ratio (adjusted difference 0.52, p < 0.001). In regression analyses, a higher…

  39. 39
    top 1.2%

    The Phenotypic Continuum of ATP1A3 -Related Disorders

    Aikaterini Vezyroglou, Rhoda Akilapa, Katy E Barwick, Saskia Koene, Catherine A. Brownstein and 24 more

    80 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200927OpenAlex

    Show abstract

    Background and Objectives ATP1A3 is associated with a broad spectrum of predominantly neurologic disorders, which continues to expand beyond the initially defined phenotypes of alternating hemiplegia of childhood, rapid-onset dystonia parkinsonism, and cerebellar ataxia, areflexia, pes cavus, optic atrophy, sensorineural hearing loss syndrome. This phenotypic variability makes it challenging to assess the pathogenicity of an ATP1A3 variant found in an undiagnosed patient. We describe the phenotypic features of individuals carrying a pathogenic/likely pathogenic ATP1A3 variant and perform a literature review of all ATP1A3 variants published thus far in association with human neurologic disease. Our aim is to demonstrate the heterogeneous clinical spectrum of the gene and look for phenotypic overlap between patients that will streamline the diagnostic process. Methods Undiagnosed individuals with ATP1A3 variants were identified within the cohort of the Deciphering Developmental Disorders study with additional cases contributed by collaborators internationally. Detailed clinical data…

  40. 40
    top 1.2%

    Development and Validation of a Prediction Model for Early Diagnosis of SCN1A -Related Epilepsies

    Andreas Brunklaus, Eduardo Pérez‐Palma, Ismael Ghanty, Xinge Ji, Eva H. Brilstra and 17 more

    78 citationsOpen accessdoi:10.1212/wnl.0000000000200028OpenAlex

    Show abstract

    Background and Objectives Pathogenic variants in the neuronal sodium channel α1 subunit gene (SCN1A) are the most frequent monogenic cause of epilepsy. Phenotypes comprise a wide clinical spectrum, including severe childhood epilepsy; Dravet syndrome, characterized by drug-resistant seizures, intellectual disability, and high mortality; and the milder genetic epilepsy with febrile seizures plus (GEFS+), characterized by normal cognition. Early recognition of a child9s risk for developing Dravet syndrome vs GEFS+ is key for implementing disease-modifying therapies when available before cognitive impairment emerges. Our objective was to develop and validate a prediction model using clinical and genetic biomarkers for early diagnosis of SCN1A-related epilepsies. Methods We performed a retrospective multicenter cohort study comprising data from patients with SCN1A-positive Dravet syndrome and patients with GEFS+ consecutively referred for genetic testing (March 2001–June 2020) including age at seizure onset and a newly developed SCN1A genetic score. A training cohort was used to develop…

  41. 41
    top 1.2%

    Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline

    Jarith L. Ebenau, Wiesje Pelkmans, Inge M.W. Verberk, Sander C.J. Verfaillie, Karlijn A. van den Bosch and 8 more

    77 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200035OpenAlex

    Show abstract

    Background and Objectives Multiple biomarkers have been suggested to measure neurodegeneration (N) in the AT(N) framework, leading to inconsistencies between studies. We investigated the association of 5 N biomarkers with clinical progression and cognitive decline in individuals with subjective cognitive decline (SCD). Methods We included individuals with SCD from the Amsterdam Dementia Cohort and SCIENCe project, a longitudinal cohort study (follow-up 4±3 years). We used the following N biomarkers: CSF total tau (t-tau), medial temporal atrophy visual rating on MRI, hippocampal volume (HV), serum neurofilament light (NfL), and serum glial fibrillary acidic protein (GFAP). We determined correlations between biomarkers. We assessed associations between N biomarkers and clinical progression to mild cognitive impairment or dementia (Cox regression) and Mini-Mental State Examination (MMSE) over time (linear mixed models). Models included age, sex, CSF β-amyloid (Aβ) (A), and CSF p-tau (T) as covariates, in addition to the N biomarker. Result We included 401 individuals (61±9 years, 42%…

  42. 42
    top 1.3%

    Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease

    Ornella V. Billette, Gabriel Ziegler, Merita Aruci, Hartmut Schütze, Jasmin M. Kizilirmak and 25 more

    76 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200667OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: We assessed whether novelty-related fMRI activity in medial temporal lobe regions and the precuneus follows an inverted U-shaped pattern across the clinical spectrum of increased Alzheimer disease (AD) risk as previously suggested. Specifically, we tested for potentially increased activity in individuals with a higher AD risk due to subjective cognitive decline (SCD) or mild cognitive impairment (MCI). We further tested whether activity differences related to diagnostic groups were accounted for by CSF markers of AD or brain atrophy. METHODS: We studied 499 participants aged 60-88 years from the German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia Study (DELCODE) who underwent task-fMRI. Participants included 163 cognitively normal (healthy control, HC) individuals, 222 SCD, 82 MCI, and 32 patients with clinical diagnosis of mild AD. CSF levels of β-amyloid 42/40 ratio and phosphorylated-tau181 were available from 232 participants. We used region-based analyses to assess novelty-related activity (novel > highly…

  43. 43
    top 1.3%

    Prolonged Cardiac Monitoring and Stroke Recurrence

    Georgios K. Tsivgoulis, Sokratis Triantafyllou, Lina Palaiodimou, Brian Mac Grory, Spyridon Deftereos and 20 more

    75 citationsdoi:10.1212/wnl.0000000000200227OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Prolonged poststroke cardiac rhythm monitoring (PCM) reveals a substantial proportion of patients with ischemic stroke (IS) with atrial fibrillation (AF) not detected by conventional rhythm monitoring strategies. We evaluated the association between PCM and the institution of stroke preventive strategies and stroke recurrence. METHODS: We searched MEDLINE and SCOPUS databases to identify studies reporting stroke recurrence rates in patients with history of recent IS or TIA receiving PCM compared with patients receiving conventional cardiac rhythm monitoring. Pairwise meta-analyses were performed under the random effects model. To explore for differences between the monitoring strategies, we combined direct and indirect evidence for any given pair of monitoring devices assessed within a randomized controlled trial (RCT). RESULTS: We included 8 studies (5 RCTs, 3 observational; 2,994 patients). Patients receiving PCM after their index event had a higher rate of AF detection and anticoagulant initiation in RCTs (risk ratio [RR] 3.91, 95% CI 2.54-6.03; RR…

  44. 44
    top 1.3%

    The Cerebral Collateral Cascade

    Tobias Djamsched Faizy, Michael Mlynash, Reza Kabiri, Sören Christensen, Gabriella M. Kuraitis and 9 more

    75 citationsdoi:10.1212/wnl.0000000000200340OpenAlex

    Show abstract

    Background and Objectives Robust cerebral collaterals are associated with favorable outcomes in patients with acute ischemic stroke due to large vessel occlusion treated by thrombectomy. However, collateral status assessment mostly relies on single imaging biomarkers and a more comprehensive holistic approach may provide deeper insights into the biology of collateral perfusion on medical imaging. Comprehensive collateralization is defined as blood flow of cerebral arteries through the brain tissue and into draining veins. We hypothesized that a comprehensive analysis of the cerebral collateral cascade (CCC) on an arterial, tissue, and venous level would predict clinical and radiologic outcomes. Methods This was a multicenter retrospective cohort study of patients with acute stroke undergoing thrombectomy triage. CCC was determined by quantifying pial arterial collaterals, tissue-level collaterals, and venous outflow (VO). Pial arterial collaterals were determined by CT angiography; tissue-level collaterals were assessed on CT perfusion. VO was assessed on CT angiography using the…

  45. 45
    top 1.4%

    Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis

    Niels Bergsland, Michael G. Dwyer, Dejan Jakimovski, Eleonora Tavazzi, Ralph H. B. Benedict and 2 more

    74 citationsOpen accessdoi:10.1212/wnl.0000000000201608OpenAlex

    Show abstract

    Background. Inflammation of the choroid plexus (CP) has been reported in multiple sclerosis (MS). The association between CP inflammation and clinical disability progression is still under debate . Objectives. To assess the relationship between measures of CP inflammation and investigate their associations with clinical disability progression in MS. Methods. In this retrospective analysis of a longitudinal study, 174 MS patients (118 with relapsing remitting MS (RRMS) and 56 with progressive MS (PMS) ) and 56 healthy controls (HCs), group matched for age and sex, were imaged on a 3T MRI scanner at baseline and after an average of 5.5 years of follow-up. T2 lesion volume (T2-LV) was assessed. Regional tissue volumes were calculated. CP volume was measured and pseudo T2 (pT2) mapping was performed to asses CP inflammation. Group comparisons and correlations were adjusted for age and sex. Results. MS patients presented with significantly larger CP volume (p = 0.01) and increased CP pT2 (< 0.001) at baseline, when compared to HCs. CP volume and CP pT2 did not significantly increase over…

  46. 46
    top 1.4%

    Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease

    Maryam Ghahremani, Meng Wang, Hung‐Yu Chen, Henrik Zetterberg, Eric Edward Smith and 2 more

    74 citationsOpen accessdoi:10.1212/wnl.0000000000201517OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Plasma phosphorylated tau at threonine 181 (p-tau181), a well-validated marker of Alzheimer disease (AD) pathologic change, could be a more efficient way to diagnose AD than invasive or expensive biomarkers requiring CSF or PET. In some individuals, neuropsychiatric symptoms (NPS) are the earliest manifestation of AD, observed in advance of clear cognitive decline. However, the few studies assessing AD biomarkers in association with NPS have often had imprecision in capturing behavioral symptoms that represent sequelae of neurodegenerative disease. Thus, the mild behavioral impairment (MBI) construct was developed, framing NPS in a way to improve the precision of risk estimates for disease. MBI core criteria stipulate that NPS emerge de novo in later life and persist for at least 6 months. Here, cross-sectionally and longitudinally, we investigated associations of MBI with p-tau181, neuropsychological test performance, and incident AD. METHODS: Cognitively unimpaired and mild cognitive impairment (MCI) Alzheimer's Disease Neuroimaging Initiative…

  47. 47
    top 1.4%

    Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease

    Meredith A. Bock, Ethan G. Brown, Li Zhang, Caroline M. Tanner

    74 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200113OpenAlex

    Show abstract

    Background and Objectives There is growing interest in health-related quality of life (HRQOL) as a comprehensive view of the patient9s well-being, guiding concept for the treating clinician, and therapeutic trial outcome measure for patients with Parkinson disease (PwPD). The key determinants of HRQOL have not been investigated in large populations of PwPD. Our objective was to evaluate correlates of HRQOL in a large, online cohort of PwPD. Methods As part of an ongoing online cohort study, we performed a cross-sectional analysis at enrollment of 23,058 PwPD. We conducted univariate and stepwise multivariate linear regression analyses of HRQOL as measured by the EQ-5D-5L tool. In addition, we performed an interaction analysis to evaluate heterogeneity of the effect of motor symptoms on HRQOL and Spearman correlation analysis to evaluate the association of nonmotor symptoms with HRQOL. Results In the multivariate linear regression model, participants with moderate or severe depression, more severe motor symptoms, and a higher burden of medical comorbidities had the most substantially…

  48. 48
    top 1.4%

    Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease

    Sandeep Grover, Ashwin Ashok Kumar Sreelatha, Lasse Pihlstrøm, Cloé Domenighetti, Claudia Schulte and 25 more

    73 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200699OpenAlex

    Show abstract

    Background and Objectives Considerable heterogeneity exists in the literature concerning genetic determinants of the age at onset (AAO) of Parkinson disease (PD), which could be attributed to a lack of well-powered replication cohorts. The previous largest genome-wide association studies (GWAS) identified SNCA and TMEM175 loci on chromosome (Chr) 4 with a significant influence on the AAO of PD; these have not been independently replicated. This study aims to conduct a meta-analysis of GWAS of PD AAO and validate previously observed findings in worldwide populations. Methods A meta-analysis was performed on PD AAO GWAS of 30 populations of predominantly European ancestry from the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson9s Disease (COURAGE-PD) Consortium. This was followed by combining our study with the largest publicly available European ancestry dataset compiled by the International Parkinson Disease Genomics Consortium (IPDGC). Results The COURAGE-PD Consortium included a cohort of 8,535 patients with PD (91.9%: Europeans and 9.1%:…

  49. 49
    top 1.5%

    Evidence-Based, Implementable Motor Rehabilitation Guidelines for Individuals With Cerebral Palsy

    Anthony Demont, Michel Gedda, Céline Lager, Capucine de Lattre, Yann Gary and 14 more

    72 citationsdoi:10.1212/wnl.0000000000200936OpenAlex

    Show abstract

    BACKGROUND: Cerebral palsy is a life-long condition that causes heterogeneous motor disorders. Motor rehabilitation interventions must be adapted to the topography of the symptoms, ambulatory capacity, and age of the individual. Current guidelines do not differentiate between the different profiles of individuals with cerebral palsy, which limits their implementation. OBJECTIVES: To develop evidence-based, implementable guidelines for motor rehabilitation interventions for individuals with cerebral palsy according to the age, topography of the cerebral palsy, and ambulatory capacity of the individual and to determine a level of priority for each intervention. METHODS: We used a mixed methods design that combined a systematic review of the literature on available motor rehabilitation interventions with expert opinions. Based on the French National Authority for Health methodology, recommendations were graded as strong, conditional, or weak. Interventions were then prioritized by the experts according to both the evidence and their own opinions on relevance and implementability to…

  50. 50
    top 1.5%

    Clinical Guidance in Neuropalliative Care

    Lynne Patricia Taylor, Jessica M. Besbris, William David Graf, Michael A. Rubin, Salvador Cruz‐Flores and 1 more

    72 citationsdoi:10.1212/wnl.0000000000200063OpenAlex

    Show abstract

    In 1974, Dr. Balfour Mount introduced the term “palliative” from the Latin word palliare—“to wrap in comfort”—as a description of an approach that supports patients by focusing on improving their quality of life through symptom control, both physical and psychological, rather than on the diagnosis and treatment of their underlying disease. He sought to separate this part of supportive care from the emerging hospice movement, which was focused solely on the end of life. In the minds of many physicians as well as the lay public, palliative care is often seen as synonymous with hospice, and therefore leads to missed opportunities for the provision of palliative services earlier in the disease process.

  51. 51
    top 1.5%

    Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort

    Jordi Sarto, Raquel Ruiz‐García, Núria Guillén, Oscar Ramos‐Campoy, Neus Falgàs and 17 more

    71 citationsOpen accessdoi:10.1212/wnl.0000000000201597OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Blood-based biomarkers have emerged as minimally invasive options for evaluating cognitive impairment. Most studies to date have assessed them in research cohorts, limiting their generalization to everyday clinical practice. We evaluated their diagnostic performance and clinical applicability in a prospective, real-world, memory clinic cohort. METHODS: All patients referred with suspected cognitive impairment between July 2019 and June 2021 were prospectively invited to participate. Five plasma biomarkers (tau phosphorylated at threonine 181 [p-tau181], glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL], total tau [t-tau], and ubiquitin C-terminal hydrolase L1 [UCH-L1]) were determined with single-molecule array. Performance was assessed in comparison to clinical diagnosis (blinded to plasma results) and amyloid status (CSF/PET). A group of cognitively unimpaired (CU) controls was also included. RESULTS: Three hundred forty-nine participants (mean age 68, SD 8.3 years) and 36 CU controls (mean age 61.7, SD 8.2 years) were included. In…

  52. 52
    top 1.6%

    Alcohol Intake as a Risk Factor for Acute Stroke

    Andrew Smyth, Martin James O'Donnell, Sumathy Rangarajan, Graeme J. Hankey, Shahram Oveisgharan and 25 more

    71 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201388OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: There is uncertainty about the association between alcohol consumption and stroke, particularly for low-moderate intake. We explored these associations in a large international study. METHODS: INTERSTROKE, a case-control study, is the largest international study of risk factors for acute stroke. Alcohol consumption was self-reported and categorized by drinks/week as low (1-7), moderate (7-14 for females and 7-21 for males), or high (>14 for females and >21 for males). Heavy episodic drinking (HED) was defined as >5 drinks on ≥1 day per month. Multivariable conditional logistic regression was used to determine associations. RESULTS: We included 12,913 cases and 12,935 controls; 25.0% (n = 6,449) were current drinkers, 16.7% (n = 4,318) former drinkers, and 58.3% (n = 15,076) never drinkers. Current drinkers were younger, male, smokers, active, and with higher-paid occupations. Current drinking was associated with all stroke (OR 1.14; 95% CI 1.04-1.26) and intracerebral hemorrhage (ICH) (OR 1.50, 95% CI 1.21-1.84) but not ischemic stroke (OR 1.06; 95% CI…

  53. 53
    top 1.6%

    Natural History of Friedreich Ataxia

    Christian Rummey, Louise A. Corben, Martin Bruce Delatycki, George R. Wilmot, Sub H. Subramony and 12 more

    71 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200913OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The understanding of the natural history of Friedreich ataxia (FRDA) has improved considerably recently, but patterns of neurologic deterioration are not fully clarified, compromising the assessment of the clinical relevance of effects and guidance for study design. The goal of this study was to acknowledge the broad genetic diversity of the population, especially for younger individuals, and to provide analyses stratified by age to guide population selection in future studies. METHODS: Based on a large natural history study, the FRDA Clinical Outcome Measures study that at the current data cut enrolled 1,115 participants, followed up for 5,287 yearly visits, we present results from the modified FRDA Rating Scale and its subscores. The secondary outcomes included the patient-reported activities of daily living scale, the timed 25-foot walk, and the 9-hole peg test. Long-term progression was modeled using slope analyses within early-onset, typical-onset, intermediate-onset, and late-onset FRDA. To reflect recruitment in clinical trials, short-term changes…

  54. 54
    top 1.6%

    β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population

    Anna Rosenberg, Ulf Öhlund‐Wistbacka, Anette Hall, Alexandre Bonnard, Göran Hagman and 6 more

    70 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201043OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: ATN (β-amyloid [Aβ], tau, neurodegeneration) system categorizes individuals based on their core Alzheimer disease (AD) biomarkers. An important potential future use for ATN is therapeutic decision-making in clinical practice once disease-modifying treatments (e.g., anti-amyloid), become widely available. In this cross-sectional study, we applied ATN and estimated potential eligibility for anti-amyloid treatment in a real-life memory clinic with biomarker assessments integrated into the routine diagnostic procedure and all specialized resources available for the implementation of novel treatments. METHODS: We included all consecutive patients at the Karolinska University Hospital Memory clinic in Solna, Stockholm, Sweden, who had their first diagnostic visit in April 2018-February 2021, informed consent for the clinic research database, and available clinical and biomarker (CSF and imaging) data. ATN classification was based on CSF Aβ42 (or Aβ42/40; A), CSF phosphorylated tau (T), and medial temporal lobe atrophy (N). For CSF markers, we applied laboratory…

  55. 55
    top 1.7%

    Physical and Mental Activity, Disease Susceptibility, and Risk of Dementia

    Jianwei Zhu, Fenfen Ge, Yu Zeng, Yuanyuan Qu, Wenwen Chen and 4 more

    70 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200701OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The association between patterns of physical/mental activity and dementia and how it is affected by disease susceptibility remains unknown. We aimed to examine the association between patterns of physical and mental activity and dementia and whether it can be modified by disease susceptibility to dementia. METHODS: genotype, and by the self-reported family history of dementia. RESULTS: genotype, or family history of dementia. DISCUSSION: Activity patterns more adherent to frequent vigorous and other exercises, housework-related activity, and friend/family visit were associated with a reduced risk of multiple types of dementia. Such associations are independent of disease susceptibility, highlighting the potential of these physical and mental activity patterns, as effective interventions, in the primary prevention of dementia.

  56. 56
    top 1.7%

    Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis

    Mar Guasp, Lorena Martín-Aguilar, Lídia Sabater, Miquel Bioque, Thaís Armangué and 11 more

    70 citationsdoi:10.1212/wnl.0000000000200021OpenAlex

    Show abstract

    Background and Objectives An important challenge in diagnosing anti–NMDA receptor (NMDAR) encephalitis (NMDARe) is differentiating it from a first episode of psychosis (FEP) caused by a psychiatric disease (pFEP). CSF antibody testing distinguishes these diseases, but spinal taps are difficult to obtain in psychiatric facilities. A separate problem is the lack of biomarkers of NMDARe severity and outcome. Here we assessed the performance of neurofilament light chain (NfL) testing in these settings. Methods In this observational study, NfL levels were determined with single-molecule array in patients with NMDARe, pFEP, herpes simplex encephalitis (HSE), and healthy participants (HC), with the last 2 groups used as controls. Receiver operating characteristic (ROC) analyses were performed to assess the prediction accuracy of serum NfL (sNfL) levels for NMDARe and pFEP and to obtain clinically useful cutoffs. Results One hundred eighteen patients with NMDARe (33 with isolated psychosis at presentation), 45 with pFEP, 36 with HSE, and 36 HC were studied. Patients with NMDARe with…

  57. 57
    top 1.7%

    Cognitive Reserve and Mild Cognitive Impairment

    Maryam Iraniparast, Yidan Shi, Ying Wu, Leilei Zeng, Colleen Jean Maxwell and 4 more

    70 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200051OpenAlex

    Show abstract

    Background and Objectives Little is known about the effect of education or other indicators of cognitive reserve on the rate of reversion from mild cognitive impairment (MCI) to normal cognition (NC) or the relative rate (RR) of reversion from MCI to NC vs progression from MCI to dementia. Our objectives were to (1) estimate transition rates from MCI to NC and dementia and (2) determine the effect of age, APOE, and indicators of cognitive reserve on the RR of reversion vs progression using multistate Markov modeling. Methods We estimated instantaneous transition rates between NC, MCI, and dementia after accounting for transition to death across up to 12 assessments in the Nun Study, a cohort study of religious sisters aged 75+ years. We estimated RRs of reversion vs progression for age, APOE, and potential cognitive reserve indicators: education, academic performance (high school grades), and written language skills (idea density, grammatical complexity). Results Of the 619 participants, 472 were assessed with MCI during the study period. Of these 472, 143 (30.3%) experienced at…

  58. 58
    top 1.7%

    Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension

    Susan P. Mollan, James Mitchell, Andreas Yiangou, Ryan S. Ottridge, Zerin Alimajstorovic and 8 more

    69 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200839OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The idiopathic intracranial hypertension randomized controlled weight trial (IIH:WT) established that weight loss through bariatric surgery significantly reduced intracranial pressure when compared with a community weight management intervention. This substudy aimed to evaluate the amount of weight loss required to reduce intracranial pressure and to explore the effect of different bariatric surgical approaches. METHODS: were randomized to bariatric surgery or a community weight management intervention (1:1). This per-protocol analysis evaluated the relationship between intracranial pressure, weight loss, and the weight loss methods. A linear hierarchical regression model was used to fit the trial outcomes, adjusted for time, treatment arm, and weight. RESULTS: ≤ 0.0001). Twenty-four percentage of weight loss (weight loss of 13.3 kg [SD 1.76]) was associated with disease remission (intracranial pressure [ICP] ≤ 25 cmCSF). Roux-en-Y gastric bypass achieved greater, more rapid, and sustained ICP reduction compared with other methods. DISCUSSION: The greater…

  59. 59
    top 1.8%

    Patient-Centered Treatment of Chronic Migraine With Medication Overuse

    Todd J. Schwedt, Joseph G. Hentz, Soma Sahai‐Srivastava, Natalia Murinova, Nicole M. Spare and 25 more

    69 citationsdoi:10.1212/wnl.0000000000200117OpenAlex

    Show abstract

    Background and Objectives Overuse of symptomatic (i.e., acute) medications is common among those with chronic migraine. It is associated with developing frequent headaches, medication side effects, and reduced quality of life. The optimal treatment strategy for patients who have chronic migraine with medication overuse (CMMO) has long been debated. The study objective was to determine whether migraine preventive therapy without switching or limiting the frequency of the overused medication was noninferior to migraine preventive therapy with switching from the overused medication to an alternative medication that could be used on ≤2 d/wk. Methods The Medication Overuse Treatment Strategy (MOTS) trial was an open-label, pragmatic clinical trial, randomizing adult participants 1:1 to migraine preventive medication and (1) switching from the overused medication to an alternative used ≤2 d/wk or (2) continuation of the overused medication with no maximum limit. Participants were enrolled between February 2017 and December 2020 from 34 clinics in the United States, including headache…

  60. 60
    top 1.8%

    Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury

    Takahiro Ushida, Yoichi Katayama, Yoichi Hiasa, Makoto Nishihara, Fumihiro Tajima and 8 more

    68 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000201709OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Patients with spinal cord injury (SCI) commonly experience central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for peripheral neuropathic pain, but evidence for CNeP is lacking. METHODS: This randomized, double-blind, placebo-controlled, phase 3 study investigated mirogabalin efficacy and safety for the treatment of CNeP in patients with traumatic SCI. Adult patients from 120 sites throughout Japan, Korea, and Taiwan were randomized (1:1) to receive placebo or mirogabalin (5 mg twice daily [BID] for 1 week, 10 mg BID for 1 week, and 10 or 15 mg BID for 12 weeks). Patients with moderate renal impairment received half the dosage. The primary efficacy endpoint was change from baseline in the weekly average daily pain score (ADPS) at week 14. The secondary endpoints included ADPS responder rates, the Short-Form McGill Pain Questionnaire (SF-MPQ), average daily sleep interference score (ADSIS), and Neuropathic Pain Symptom Inventory (NPSI). Adverse events were monitored for safety. RESULTS: = 0.0001). Responder rates at week…

  61. 61
    top 1.8%

    Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies

    Simone de Vries Lentsch, Britt W. H. van der Arend, Antoinette MaassenVanDenBrink, Gisela Marie Terwindt

    68 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201008OpenAlex

    Show abstract

    Background and Objectives Anti–calcitonin gene-related peptide (CGRP) (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of postmarketing case reports of elevated blood pressure (BP) associated with erenumab. In this prospective follow-up study, we aimed to assess the safety regarding BP in a real-world setting. Methods All people with migraine who were treated with erenumab and fremanezumab at the Leiden Headache Center between January 2019 and January 2021 were included. BP measurements were collected from baseline (T0) until 12 months of follow-up, with a 3-month interval (T1–T4). Mixed linear models were fitted with time as a fixed effect and the patient as a random effect. Results Both systolic and diastolic BP were increased at all time points T1–T4 compared with T0 (p < 0.001). The maximum estimated increase in the mean systolic BP was 5.2 mm Hg (95% CI 3.1–7.5). The maximum estimated increase in the mean diastolic BP was 3.5 mm Hg (95% CI 2.0–4.9). In the erenumab group (n = 109), both…

  62. 62
    top 1.9%

    Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk

    Bowen Tang, Yunzhang Wang, Xia Jiang, Madhav Thambisetty, Luigi Ferrucci and 2 more

    67 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200771OpenAlex

    Show abstract

    Background and Objectives Previous studies have highlighted antidiabetic drugs as repurposing candidates for Alzheimer disease (AD), but the disease-modifying effects are still unclear. Methods A 2-sample mendelian randomization study design was applied to examine the association between genetic variation in the targets of 4 antidiabetic drug classes and AD risk. Genetic summary statistics for blood glucose were analyzed using UK Biobank data of 326,885 participants, whereas summary statistics for AD were retrieved from previous genome-wide association studies comprising 24,087 clinically diagnosed AD cases and 55,058 controls. Positive control analysis on type 2 diabetes mellitus (T2DM), insulin secretion, insulin resistance, and obesity-related traits was conducted to validate the selection of instrumental variables. Results In the positive control analysis, genetic variation in sulfonylurea targets was associated with higher insulin secretion, a lower risk of T2DM, and an increment in body mass index, waist circumference, and hip circumference, consistent with drug mechanistic…

  63. 63
    top 1.9%

    Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis

    Ryan L. Davis, Kishore Raj Kumar, Clare Puttick, Christina Liang, Kate E. Ahmad and 10 more

    67 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200745OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Mitochondrial diseases (MDs) are the commonest group of heritable metabolic disorders. Phenotypic diversity can make molecular diagnosis challenging, and causative genetic variants may reside in either mitochondrial or nuclear DNA. A single comprehensive genetic diagnostic test would be highly useful and transform the field. We applied whole-genome sequencing (WGS) to evaluate the variant detection rate and diagnostic capacity of this technology with a view to simplifying and improving the MD diagnostic pathway. METHODS: Adult patients presenting to a specialist MD clinic in Sydney, Australia, were recruited to the study if they satisfied clinical MD (Nijmegen) criteria. WGS was performed on blood DNA, followed by clinical genetic analysis for known pathogenic MD-associated variants and MD mimics. RESULTS: Of the 242 consecutive patients recruited, 62 participants had "definite," 108 had "probable," and 72 had "possible" MD classification by the Nijmegen criteria. Disease-causing variants were identified for 130 participants, regardless of the location of…

  64. 64
    top 1.9%

    Multivariable Prediction Model for Futile Recanalization Therapies in Patients With Acute Ischemic Stroke

    Thomas R. Meinel, Christine Lerch, Urs Fischer, Morin Beyeler, Adnan Mujanović and 14 more

    66 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200815OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Very poor outcome despite IV thrombolysis (IVT) and mechanical thrombectomy (MT) occurs in approximately 1 of 4 patients with ischemic stroke and is associated with a high logistic and economic burden. We aimed to develop and validate a multivariable prognostic model to identify futile recanalization therapies (FRTs) in patients undergoing those therapies. METHODS: Patients from a prospectively collected observational registry of a single academic stroke center treated with MT and/or IVT were included. The data set was split into a training (N = 1,808, 80%) and internal validation (N = 453, 20%) cohort. We used gradient boosted decision tree machine learning models after k-nearest neighbor imputation of 32 variables available at admission to predict FRT defined as modified Rankin scale 5-6 at 3 months. We report feature importance, ability for discrimination, calibration, and decision curve analysis. RESULTS: A total of 2,261 patients with a median (interquartile range) age of 75 years (64-83 years), 46% female, median NIH Stroke Scale 9 (4-17), 34% IVT…

  65. 65
    top 1.9%

    Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults

    Michelle E. Farrell, Kathryn V. Papp, Rachel F. Buckley, Heidi I.L. Jacobs, Aaron P. Schultz and 6 more

    66 citationsOpen accessdoi:10.1212/wnl.0000000000200137OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Alzheimer disease (AD) clinical trials are moving earlier in the disease process according to emerging signs of β-amyloid (Aβ) and tau pathology. If early treatment is the right time for intervention, it is critical to find the right test to optimize cognitive outcome measures for clinical trials. We sought to identify cognitive measures associated with the earliest detectable signs of emerging Aβ and tau pathology. METHODS: F-flortaucipir (FTP)-PET, and cognitive data for ≥7 years were included from the Harvard Aging Brain Study (HABS). Analyses assessed those initially classified as PiB- (less than Centiloid [CL] 20) and then expanded to include PiB+ individuals up to CL40, the approximate threshold beyond which neocortical tau proliferation begins. Separate linear mixed-effects models assessed the effects of emerging global Aβ (PiB slope) and tau (baseline FTP level and FTP slope) in the entorhinal and inferior temporal (IT) cortices on multiple cognitive tasks and the Preclinical Alzheimer's Cognitive Composite (PACC) over time. RESULTS: Steeper PiB…

  66. 66
    top 2%

    Trajectories of Neurologic Recovery 12 Months After Hospitalization for COVID-19

    Jennifer Ann Frontera, Dixon Yang, Chaitanya B. Medicherla, Samuel Baskharoun, Kristie Bauman and 25 more

    66 citationsOpen accessdoi:10.1212/wnl.0000000000200356OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVE: Little is known about trajectories of recovery 12 months after hospitalization for severe COVID-19. METHODS: We conducted a prospective, longitudinal cohort study of patients with and without neurologic complications during index hospitalization for COVID-19 from March 10, 2020, to May 20, 2020. Phone follow-up batteries were performed at 6 and 12 months after COVID-19 onset. The primary 12-month outcome was the modified Rankin Scale (mRS) score comparing patients with or without neurologic complications using multivariable ordinal analysis. Secondary outcomes included activities of daily living (Barthel Index), telephone Montreal Cognitive Assessment (t-MoCA), and Quality of Life in Neurologic Disorders (Neuro-QoL) batteries for anxiety, depression, fatigue, and sleep. Changes in outcome scores from 6 to 12 months were compared using nonparametric paired-samples sign test. RESULTS: = 0.003). Nonsignificant improvements occurred in fatigue, sleep, and depression scores in 48%, 48%, and 38% of patients, respectively. Barthel Index and mRS scores remained…

  67. 67
    top 2%

    Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis

    Ingrid Anne Lie, Merlin M. Weeda, Rozemarijn Margaretha Mattiesing, Marijke A.E. Mol, Petra J. W. Pouwels and 5 more

    66 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200006OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: There is currently no consensus about the extent of gray matter (GM) atrophy that can be attributed to secondary changes after white matter (WM) lesions or the temporal and spatial relationships between the 2 phenomena. Elucidating this interplay will broaden the understanding of the combined inflammatory and neurodegenerative pathophysiology of multiple sclerosis (MS), and separating atrophic changes due to primary and secondary neurodegenerative mechanisms will then be pivotal to properly evaluate treatment effects, especially if these treatments target the different processes individually. To untangle these complex pathologic mechanisms, this systematic review provides an essential first step: an objective and comprehensive overview of the existing in vivo knowledge of the relationship between brain WM lesions and GM atrophy in patients diagnosed with MS. The overall aim was to clarify the extent to which WM lesions are associated with both global and regional GM atrophy and how this may differ in the different disease subtypes. METHODS: We searched…

  68. 68
    top 2%

    Intake of Flavonoids and Flavonoid-Rich Foods and Mortality Risk Among Individuals With Parkinson Disease

    Xinyuan Zhang, Samantha A. Molsberry, Tian‐Shin Yeh, Aedín Cassidy, Michael A. Schwarzschild and 2 more

    66 citationsOpen accessdoi:10.1212/wnl.0000000000013275OpenAlex

    Show abstract

    Background and Objectives Although flavonoids have the potential to exert neuroprotective benefits, evidence of their role in improving survival rates among individuals with Parkinson disease (PD) remains lacking. We aimed to prospectively study the association between prediagnosis and postdiagnosis flavonoid intakes and risk of mortality among individuals with PD identified from 2 large ongoing cohorts of US men and women. Methods Included in the current analysis were 599 women from the Nurses9 Health Study and 652 men from the Health Professionals Follow-Up Study who were newly diagnosed with PD during follow-up. Dietary intakes of total flavonoid and its subclasses, together with major flavonoid-rich foods (tea, apples, berries, orange and orange juice, and red wine), were repeatedly assessed with a validated food frequency questionnaire every 4 years. Mortality was ascertained via the National Death Index and state vital statistics records. Results We documented 944 deaths during 32 to 34 years of follow-up. A higher total flavonoid intake before PD diagnosis was associated with…

  69. 69
    top 2.1%

    Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations

    Jessica Ailani, Eric A. Kaiser, Paul G. Mathew, Peter McAllister, Andrew F. Russo and 6 more

    65 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000201332OpenAlex

    Show abstract

    Calcitonin gene-related peptide (CGRP) is involved in several of the pathophysiologic processes underpinning migraine attacks. Therapies that target CGRP or its receptor have shown efficacy as preventive or acute treatments for migraine. Two small-molecule CGRP receptor antagonists (rimegepant and ubrogepant) are approved for the acute treatment of migraine, and 4 monoclonal antibodies (eptinezumab, erenumab, fremanezumab, and galcanezumab) are approved for migraine prevention; erenumab targets the canonical CGRP receptor, the others CGRP ligand. CGRP plays a role in gastrointestinal nociception, inflammation, gastric acid secretion, and motility. Nausea and vomiting are among the gastrointestinal symptoms associated with migraine, but individuals with migraine may also experience functional upper and lower gastrointestinal comorbidities, such as gastroesophageal reflux disease, gastroparesis, functional diarrhea or constipation, and irritable bowel syndrome. Although gastrointestinal symptoms in migraine can be treatment-related, they may also be attributable to increased CGRP. In…

  70. 70
    top 2.1%

    Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke

    Merelijne A. Verschoof, Adrien E.D. Groot, Sebastiaan F.T.M. de Bruijn, Bob Roozenbeek, H. Bart van der Worp and 25 more

    65 citationsOpen accessdoi:10.1212/wnl.0000000000013316OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: To explore clinical and safety outcomes of patients with acute ischemic stroke (AIS) and active cancer after endovascular treatment (EVT). METHODS: Using data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry, we compared patients with active cancer (defined as cancer diagnosed within 12 months before stroke, metastatic disease, or current cancer treatment) to patients without cancer. Outcomes were 90-day modified Rankin Scale (mRS) score, mortality, successful reperfusion (expanded Treatment in Cerebral Infarction score ≥2b), symptomatic intracranial hemorrhage (sICH), and recurrent stroke. Subgroup analyses were performed in patients with a prestroke mRS score of 0 or 1 and according to treatment setting (curative or palliative). Analyses were adjusted for prognostic variables. RESULTS: Of 2,583 patients who underwent EVT, 124 (4.8%) had active cancer. They more often had prestroke disability (mRS score ≥2: 34.1% vs 16.6%). The treatment setting was palliative in…

  71. 71
    top 2.1%

    Ketamine for Management of Neonatal and Pediatric Refractory Status Epilepticus

    Marin Jacobwitz, Caitlyn Mulvihill, Michael C. Kaufman, Alexander K. Gonzalez, Karla Resendiz and 5 more

    64 citationsOpen accessdoi:10.1212/wnl.0000000000200889OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Few data are available regarding the use of anesthetic infusions for refractory status epilepticus (RSE) in children and neonates, and ketamine use is increasing despite limited data. We aimed to describe the impact of ketamine for RSE in children and neonates. METHODS: Retrospective single-center cohort study of consecutive patients admitted to the intensive care units of a quaternary care children's hospital treated with ketamine infusion for RSE. RESULTS: Sixty-nine patients were treated with a ketamine infusion for RSE. The median age at onset of RSE was 0.7 years (interquartile range 0.15-7.2), and the cohort included 13 (19%) neonates. Three patients (4%) had adverse events requiring intervention during or within 12 hours of ketamine administration, including hypertension in 2 patients and delirium in 1 patient. Ketamine infusion was followed by seizure termination in 32 patients (46%), seizure reduction in 19 patients (28%), and no change in 18 patients (26%). DISCUSSION: Ketamine administration was associated with few adverse events, and seizures…

  72. 72
    top 2.1%

    Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs

    Helen-Margaret Onuorah, Odelin Charron, Ethan Meltzer, Amanda Montague, Alexis Crispino and 3 more

    64 citationsdoi:10.1212/wnl.0000000000013230OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Black and Hispanic people with multiple sclerosis (MS) (pMS) have been found to have different disease courses or worse outcomes associated with MS compared to White pMS. They are also more likely to be negatively affected by social determinants of health, further worsening disparities in outcomes. As these disparities may affect treatment response, non-White pMS must be included in trials for greater generalizability of research and therefore more inclusive treatment plans. In this study, we aimed to evaluate how representation of non-White groups in phase III trials of approved disease-modifying therapies (DMTs) has evolved over time and how race and ethnicity are reported in medical journals and on manufacturer websites. METHODS: We conducted a systematic review of the PubMed database from 1995 to June 2020 to identify manufacturer-sponsored phase III trials for Food and Drug Administration-approved MS DMTs. We explored how race and ethnicity were reported in trial publications. Using studies where information was available, we analyzed the…

  73. 73
    top 2.2%

    Association of Combined Healthy Lifestyle Factors With Incident Dementia in Patients With Type 2 Diabetes

    Bin Wang, Ningjian Wang, Ying B Sun, Xiao Wei Tan, Jihui Zhang and 1 more

    63 citationsdoi:10.1212/wnl.0000000000201231OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Type 2 diabetes and lifestyle factors have been associated with dementia risk, but the effect of a healthy lifestyle on diabetes-related dementia remains largely unknown. We aimed to investigate whether the increased risk of dementia among individuals with diabetes can be offset by a broad combination of healthy lifestyle factors. METHODS: This prospective study used data from the UK Biobank cohort. An overall lifestyle score ranging from 0 to 7 was created, with 1 point for each of the 7 healthy lifestyle factors: no current smoking, moderate alcohol consumption, regular physical activity, healthy diet, adequate sleep duration, less sedentary behavior, and frequent social contact. Incident dementia was ascertained using linkage with electronic health records. Cox proportional hazards models were used to examine the associations between diabetes, healthy lifestyle score, and dementia incidence. RESULTS: We included 167,946 participants aged 60 years or older without dementia at baseline (mean age 64.1 [SD 2.8] years, 51.7% female). During a median…

  74. 74
    top 2.2%

    Association of Ambient Particulate Matter Pollution of Different Sizes With In-Hospital Case Fatality Among Stroke Patients in China

    Miao Cai, Shiyu Zhang, Xiaojun Lin, Zhengmin Min Qian, Stephen Edward McMillin and 4 more

    63 citationsdoi:10.1212/wnl.0000000000200546OpenAlex

    Show abstract

    Background and Objectives To characterize the association of ambient particulate matter (PM) pollution of different sizes (PM ≤1 µm in aerodynamic diameter [PM1], PM2.5, and PM10) with in-hospital case fatality among patients with stroke in China. Methods We collected hospitalizations due to stroke in 4 provinces in China from 2013 to 2019. Seven-day and annual averages of PM prior to hospitalization were estimated using bilinear interpolation and residential addresses. Associations with in-hospital case fatality were estimated using random-effects logistic regression models. Potential reducible fraction and the number of fatalities attributed to PM were estimated using a counterfactual approach. Results Among 3,109,634 stroke hospitalizations (mean age 67.23 years [SD 12.22]; 1,765,644 [56.78%] male), we identified 32,140 in-hospital stroke fatalities (case fatality rate 1.03%). Each 10 µg/m3 increase in 7-day average (short-term) exposure to PM was associated with increased in-hospital case fatality: odds ratios (ORs) were 1.058 (95% CI 1.047–1.068) for PM1, 1.037 (95% CI…

  75. 75
    top 2.2%

    Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering

    Jari K. Gool, Zhongxing Zhang, Martijn S.S.L. Oei, Stephanie Mathias, Yves A Dauvilliers and 24 more

    63 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200519OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Recent studies fueled doubts as to whether all currently defined central disorders of hypersomnolence are stable entities, especially narcolepsy type 2 and idiopathic hypersomnia. New reliable biomarkers are needed, and the question arises of whether current diagnostic criteria of hypersomnolence disorders should be reassessed. The main aim of this data-driven observational study was to see whether data-driven algorithms would segregate narcolepsy type 1 and identify more reliable subgrouping of individuals without cataplexy with new clinical biomarkers. METHODS: We used agglomerative hierarchical clustering, an unsupervised machine learning algorithm, to identify distinct hypersomnolence clusters in the large-scale European Narcolepsy Network database. We included 97 variables, covering all aspects of central hypersomnolence disorders such as symptoms, demographics, objective and subjective sleep measures, and laboratory biomarkers. We specifically focused on subgrouping of patients without cataplexy. The number of clusters was chosen to be the minimal…

  76. 76
    top 2.3%

    Determinants of Perivascular Spaces in the General Population

    Tavia E. Evans, Maria J. Knol, Petra Schwingenschuh, Katharina Wittfeld, Saima Hilal and 15 more

    62 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201349OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Perivascular spaces (PVS) are emerging markers of cerebral small vessel disease (CSVD), but research on their determinants has been hampered by conflicting results from small single studies using heterogeneous rating methods. In this study, we therefore aimed to identify determinants of PVS burden in a pooled analysis of multiple cohort studies using 1 harmonized PVS rating method. METHODS: genotypes, and other imaging markers of CSVD. Negative binomial regression models were used to examine the association between these determinants and PVS counts. RESULTS: ε4-alleles (1.02 [1.01-1.04]). Furthermore, white matter hyperintensity volume and presence of lacunes were associated with PVS in multiple regions, but most strongly with the basal ganglia (1.13 [1.12-1.14] and 1.10 [1.09-1.12], respectively). DISCUSSION: Various factors are associated with the burden of PVS, in part regionally specific, which points toward a multifactorial origin beyond what can be expected from PVS-related risk factor profiles. This study highlights the power of collaborative…

  77. 77
    top 2.3%

    Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies

    Fabrizio Piazza, Silvia Paola Caminiti, Marialuisa Zedde, Luca Presotto, Jacopo Cosimo DiFrancesco and 6 more

    62 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200892OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Amyloid-related imaging abnormalities suggestive of vasogenic edema or sulcal effusion (ARIA-E) are the most common adverse events complicating Alzheimer disease (AD) immunotherapy with anti-β-amyloid (Aβ) monoclonal antibodies. ARIA-E can also occur spontaneously in cerebral amyloid angiopathy-related inflammation (CAA-ri), a rare autoimmune encephalopathy associated with increased CSF levels of anti-Aβ autoantibodies. Although the pathophysiologic mechanisms of ARIA-E remain to be fully elucidated, experimental evidence from ex vivo studies suggests that gantenerumab and aducanumab enable microglial activation. However, the in vivo evidence for a direct association between neuroinflammation and ARIA-E in patients with high CSF anti-Aβ (auto)antibody levels has never been demonstrated. METHODS: C-PK11195 PET for activated microglia. RESULTS: At (sub)acute presentation, we found focal peaks of microglial activation having a greater spatial colocalization with ARIA-E compared with chronic age-related white matter change imaging abnormalities. The severity…

  78. 78
    top 2.3%

    Determining Vascular Risk Factors for Dementia and Dementia Risk Prediction Across Mid- to Later Life

    Emer R. McGrath, Alexa Beiser, Adrienne O’Donnell, Jayandra Jung Himali, Matthew Paul Pase and 2 more

    62 citationsOpen accessdoi:10.1212/wnl.0000000000200521OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The association between vascular risk factors and dementia varies with age, making generalizability of dementia risk prediction rules to individuals of different ages challenging. We determined the most important vascular risk factors for inclusion in age-specific dementia risk scores. METHODS: Framingham Heart Study Original and Offspring cohort participants with available data on the Framingham Stroke Risk Profile (FSRP) at midlife (age 55; n = 4,899, 57% women), late life (ages 65 or 70), or later life (ages 75 or 80 [n = 2,386, 62% women]) were followed for 10-year incident dementia risk from ages 65, 70, 75, and 80. RESULTS: Age- and sex-adjusted midlife risk factors associated with 10-year risk of dementia from age 65 included FSRP (hazard ratio [HR] 1.16, 95% CI 1.06-1.26, per 1 SD increment in log-transformed score), diabetes mellitus (DM; HR 4.31, 95% CI 1.97-9.43), and systolic blood pressure (SBP; HR 1.12, 95% CI 1.02-1.24, per 10 mm Hg increment). Late-life risk factors associated with 10-year incident dementia from ages 65 or 70 included FSRP…

  79. 79
    top 2.3%

    Directionality of the Association Between Epilepsy and Depression

    Eva Bølling‐Ladegaard, Julie Werenberg Dreier, Lars Vedel Kessing, Esben Budtz–Jørgensen, Kasper Lolk and 1 more

    61 citationsOpen accessdoi:10.1212/wnl.0000000000201542OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Epilepsy and depression share a bidirectional relationship; however, its magnitude and long-term temporal association remain to be elucidated. This study investigates the magnitude and long-term association between epilepsy and depression, comparing with the risks of the 2 disorders after another chronic medical illness (asthma). METHODS: In a nationwide register-based matched cohort study, we identified all individuals who received a first diagnosis of epilepsy, depression, and asthma from January 1, 1980, to December 31, 2016. We used a Cox regression model to estimate the risk of epilepsy after depression and vice versa and the risk of epilepsy or depression after asthma, compared with healthy references matched on age and sex, adjusting for medical comorbidity, substance abuse, and calendar time. Results were stratified by epilepsy subtype. We furthermore investigated the risk of admission with acute seizures for persons with epilepsy who became depressed. RESULTS: In a population of 8,741,955 individuals, we identified 139,014 persons with epilepsy…

  80. 80
    top 2.4%

    Menopausal Vasomotor Symptoms and White Matter Hyperintensities in Midlife Women

    Rebecca C. Thurston, Minjie Wu, Yue‐Fang Chang, Howard Jay Aizenstein, Carol A. Derby and 2 more

    61 citationsOpen accessdoi:10.1212/wnl.0000000000201401OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The menopause transition is increasingly recognized as a time of importance for women's brain health. A growing body of work indicates that the classic menopausal symptom, vasomotor symptom (VMS), may be associated with poorer cardiovascular health. Other work links VMS to poorer cognition. We investigate whether VMS, when rigorously assessed using physiologic measures, are associated with greater white matter hyperintensity volume (WMHV) among midlife women. We consider a range of potential explanatory factors in these associations and explore whether VMS are associated with the spatial distribution of WMHV. METHODS: Women aged 45-67 years and free of hormone therapy underwent 24 hours of physiologic VMS monitoring (sternal skin conductance), actigraphy assessment of sleep, physical measures, phlebotomy, and 3 Tesla neuroimaging. Associations between VMS (24-hour, wake, and sleep VMS, with wake and sleep intervals defined by actigraphy) and whole brain WMHV were considered in linear regression models adjusted for age, race, education, smoking, body mass…

  81. 81
    top 2.4%

    Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease

    Ayda Rostamzadeh, Lara Bohr, Michael Wagner, Christopher Baethge, Frank Jessen

    61 citationsdoi:10.1212/wnl.0000000000201072OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: The risk of mild cognitive impairment (MCI) or dementia in individuals with subjective cognitive decline (SCD) and biomarkers indicating Alzheimer disease (AD) pathology in comparison with individuals with SCD without biomarker evidence for AD is critical to delineate the potential role of biomarker assessment in this group. We performed a meta-analysis of studies on this topic. METHODS: Three databases (PubMed, PsycINFO, and Cochrane) were searched from inception to May 7, 2021. Search strings included the terms: subjective cognitive decline, biomarker, amyloid, tau, risk, Alzheimer, mild cognitive impairment, and dementia. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines, 2 researchers independently performed literature search, data collection, and data extraction. We summarized odds ratios (ORs) in random-effects meta-analyses and calculated sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs), and likelihood ratios. The primary outcome was the OR of…

  82. 82
    top 2.4%

    Natural History Study of STXBP1-Developmental and Epileptic Encephalopathy Into Adulthood

    Hannah Stamberger, David Crosiers, Ganna Balagura, Claudia Maria Bonardi, Anna Purna Basu and 25 more

    61 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200715OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: variants cause a severe early-onset developmental and epileptic encephalopathy (STXBP1-DEE). We aimed to investigate the natural history of STXBP1-DEE in adults focusing on seizure evolution, the presence of movement disorders, and the level of functional (in)dependence. METHODS: variant were recruited through medical genetics departments and epilepsy centers. Treating clinicians completed clinical questionnaires and performed semistructured video examinations while performing tasks from the (modified) Unified Parkinson Disease Rating Scale when possible. RESULTS: Thirty adult patients were included for summary statistics, with video recordings available for 19 patients. The median age at last follow-up was 24 years (range 18-58 years). All patients had epilepsy, with a median onset age of 3.5 months. At last follow-up, 80% of adults had treatment-resistant seizures despite long periods of seizure freedom in 37%. Tonic-clonic, focal, and tonic seizures were most frequent in adults. Epileptic spasms, an unusual feature beyond infancy, were present in 3…

  83. 83
    top 2.5%

    Socioeconomic Status, Biological Aging, and Memory in a Diverse National Sample of Older US Men and Women

    Justina F. Avila‐Rieger, Indira C. Turney, Jet M. J. Vonk, Precious Esie, Dominika Šeblová and 3 more

    60 citationsOpen accessdoi:10.1212/wnl.0000000000201032OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Exposure to socioeconomic disadvantage is associated with early-onset cognitive aging. Biological aging, the progressive loss of system integrity that occurs as we age, is proposed as a modifiable process mediating this health inequality. We examined whether socioeconomic disparities in cognitive aging in mid-to late-life adults is explained by accelerated biological aging similarly across race, ethnicity, and sex/gender. METHODS: Data were from a prospective cohort study of the US Health and Retirement Study DNA methylation substudy. Socioeconomic status (SES) was measured from years of education and household wealth at baseline. The extent and pace of biological aging were quantified using 3 DNA methylation measures: PhenoAge, GrimAge, and DunedinPoAm. Cognitive aging was measured from repeated longitudinal assessments of immediate and delayed word recall. Latent growth curve modeling estimated participants' level of memory performance and rate of decline over 2-11 follow-up assessments spanning 2-20 years. Multiple-group models were estimated to assess…

  84. 84
    top 2.5%

    Prevalence and Risk Factors for Pharmacoresistance in Children With Focal Cortical Dysplasia–Related Epilepsy

    Nathan T. Cohen, Phat Ly Chang, Xiaozhen You, Anqing Zhang, Kathryn A. Havens and 4 more

    60 citationsOpen accessdoi:10.1212/wnl.0000000000201033OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Focal cortical dysplasia (FCD) is the most common cause of surgically remediable epilepsy in children. Little is known about the risk factors for the timing and development of pharmacoresistance in this population. This study sought to evaluate the prevalence and risk factors for pharmacoresistance in pediatric FCD-related epilepsy. METHODS: In this retrospective single-center cohort design, patients were identified from search of centralized radiology report database and a central epilepsy surgical database. Inclusion criteria consisted of 3T MRI-confirmed FCD from January, 2011, to January, 2020; ages 0 days to 22 years at MRI; and at least 18 months of documented follow-up after MRI, unless had single seizure or incidentally discovered FCD. Records were excluded if there was dual pathology (except for mesial temporal sclerosis), hemimegalencephaly, or tuberous sclerosis complex present in imaging or history. RESULTS: One hundred forty-three patients with confirmed FCD met the inclusion criteria. One hundred twenty-four children had epilepsy (87% of…

  85. 85
    top 2.5%

    Pilot Randomized Clinical Trial of a Goals-of-Care Decision Aid for Surrogates of Patients With Severe Acute Brain Injury

    Susanne Muehlschlegel, Kelsey J. Goostrey, Julie Flahive, Qiang Zhang, Jolanta J. Pach and 1 more

    60 citationsOpen accessdoi:10.1212/wnl.0000000000200937OpenAlex

    Show abstract

    Background and Objectives Breakdowns in clinician-family communication in neurologic intensive care units (neuroICUs) are common, particularly for goals-of-care decisions to continue or withdraw life-sustaining treatments while considering long-term prognoses. Shared decision-making interventions (decision aids [DAs]) may prevent this problem and increase patient-centered care, yet none are currently available. We assessed the feasibility, acceptability, and perceived usefulness of a DA for goals-of-care communication with surrogate decision makers for critically ill patients with severe acute brain injury (SABI) after hemispheric acute ischemic stroke, intracerebral hemorrhage, or traumatic brain injury. Methods We conducted a parallel-arm, unblinded, patient-level randomized, controlled pilot trial at 2 tertiary care US neuroICUs and randomized surrogate participants 1:1 to a tailored paper-based DA provided to surrogates before clinician-family goals-of-care meetings or usual care (no intervention before clinician-family meetings). The primary outcomes were feasibility of…

  86. 86
    top 2.6%

    Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition

    Tian Xiao, Laurens A. van Kleef, M. Kamran Ikram, Robert Jacobus de Knegt, M. Arfan Ikram

    60 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000200770OpenAlex

    Show abstract

    Background and Objectives Nonalcoholic fatty liver disease (NAFLD) might affect brain health via the so-called liver-brain axis. Whether this results in an increased risk for dementia remains unclear. Therefore, we investigated the association of NAFLD and fibrosis with incident dementia and cognition among the elderly. Methods We performed longitudinal and cross-sectional analyses within the Rotterdam Study, an ongoing prospective cohort. Participants visiting between 1997 and 2002 with available fatty liver index (FLI) (set 1) or participants visiting between 2009 and 2014 with abdominal ultrasound (set 2) and liver stiffness (set 3) were included. Exclusion criteria were secondary causes for steatosis, prevalent dementia, and missing alcohol data. NAFLD was defined as FLI ≥60 or steatosis on ultrasound and fibrosis as liver stiffness ≥8.0 kPa. Dementia was defined according to the DSM-III-R. Associations between NAFLD, fibrosis, or liver stiffness and incident dementia were quantified using Cox regression. Finally, the association between NAFLD and cognitive function was assessed…

  87. 87
    top 2.6%

    Clinical Features, Neuropathology, and Surgical Outcome in Patients With Refractory Epilepsy and Brain Somatic Variants in the SLC35A2 Gene

    Carmen Barba, Ingmar Blümcke, Melodie R. Winawer, Till Hartlieb, Hoon‐Chul Kang and 25 more

    59 citationsOpen accessdoi:10.1212/wnl.0000000000201471OpenAlex

    Show abstract

    Background and Objectives The SLC35A2 gene, located at chromosome Xp11.23, encodes for a uridine diphosphate–galactose transporter. We describe clinical, genetic, neuroimaging, EEG, and histopathologic findings and assess possible predictors of postoperative seizure and cognitive outcome in 47 patients with refractory epilepsy and brain somatic SLC35A2 gene variants. Methods This is a retrospective multicenter study where we performed a descriptive analysis and classical hypothesis testing. We included the variables of interest significantly associated with the outcomes in the generalized linear models. Results Two main phenotypes were associated with brain somatic SLC35A2 variants: (1) early epileptic encephalopathy (EE, 39 patients) with epileptic spasms as the predominant seizure type and moderate to severe intellectual disability and (2) drug-resistant focal epilepsy (DR-FE, 8 patients) associated with normal/borderline cognitive function and specific neuropsychological deficits. Brain MRI was abnormal in all patients with EE and in 50% of those with DR-FE. Histopathology review…

  88. 88
    top 2.6%

    Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

    Nour K. Majbour, Jan Olav Aasly, Ilham Y. Abdi, Simona S. Ghanem, Daniel Erskine and 2 more

    59 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000201199OpenAlex

    Show abstract

    Background and Objectives Robust biomarkers that can mirror Parkinson disease (PD) are of great significance. In this study, we present a novel approach to investigate disease-associated α-synuclein (αSyn) aggregates as biomarkers of PD clinical stage. Methods We combined both seed amplification assay (SAA) and ELISA to provide a quantitative test readout that reflects the clinical severity of patients with PD. To attain this goal, we initially explored the potential of our test using 2 sets of human brain homogenates (pilot and validation sets) and then verified it with 2 independent human CSF cohorts; discovery (62 patients with PD and 34 controls) and validation (49 patients with PD and 48 controls) cohorts. Results We showed that oligomers-specific ELISA robustly quantified SAA end product from patients with PD or dementia with Lewy bodies with high sensitivity and specificity scores (100%). Analysis also demonstrated that seeding activity could be detected earlier with oligomeric ELISA as the test readout rather than SAA alone. Of more importance, multiplexing the assays…

  89. 89
    top 2.6%

    Lifestyle Interventions for the Prevention of Parkinson Disease

    Jules M. Janssen Daalen, Sabine Schootemeijer, Edo Richard, Sirwan K.L. Darweesh, Bastiaan R. Bloem

    59 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200787OpenAlex

    Show abstract

    The prevalence of Parkinson disease (PD) is growing fast, amplifying the quest for disease-modifying therapies in early disease phases where pathology is still limited. Lifestyle interventions offer a promising avenue for preventing progression from prodromal to manifest PD. We illustrate this primarily for 1 specific lifestyle intervention, namely aerobic exercise because the case for the other main lifestyle factor (dietary interventions) to modify the course of prodromal PD is currently less persuasive. Various observations have hinted at the disease-modifying potential of exercise. First, studies in rodents with experimental parkinsonism showed that exercise elicits adaptive neuroplasticity in basal ganglia circuitries. Second, exercise is associated with a reduced risk of developing PD, suggesting a disease-modifying potential. Third, 2 large trials in persons with manifest PD indicate that exercise can help to stabilize motor parkinsonism, although this could also reflect a symptomatic effect. In addition, exercise seems to be a feasible intervention, given its minimal risk of…

  90. 90
    top 2.7%

    Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy

    Iñigo Ruíz‐Barrio, Yasuo Miki, Zane Jaunmuktane, Thomas T. Warner, Eduardo De Pablo‐Fernández

    58 citationsOpen access (PUBLIC-DOMAIN)doi:10.1212/wnl.0000000000201659OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Orthostatic hypotension (OH) increases dementia risk in patients with Parkinson disease (PD), although the underlying mechanisms and whether a similar association between OH and cognitive impairment exists in other synucleinopathies remain unknown. The aim is to evaluate the association between OH and dementia risk in patients with PD, and cognitive impairment risk in patients with multiple system atrophy (MSA), and to explore relevant clinical and neuropathologic factors to understand underlying pathogenic mechanisms. METHODS: This is a retrospective cohort study. Medical records throughout the entire disease course of consecutive patients with neuropathology-confirmed PD and MSA from the Queen Square Brain Bank were systematically reviewed. Time of onset and severity of OH-related symptoms were documented, and their association with other clinical and neuropathologic variables was evaluated. Dementia risk for patients with PD and cognitive impairment risk for patients with MSA were estimated using multivariable hazard regression. RESULTS: One hundred…

  91. 91
    top 2.7%

    Association of Stroke Lesion Pattern and White Matter Hyperintensity Burden With Stroke Severity and Outcome

    Anna Katharina Bonkhoff, Sung‐Min Hong, Martin Bretzner, Markus D. Schirmer, Robert William Regenhardt and 25 more

    58 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200926OpenAlex

    Show abstract

    Abstract Objective To examine whether high white matter hyperintensity (WMH) burden is associated with greater stroke severity and worse functional outcomes in lesion pattern-specific ways. Methods MR neuroimaging and National Institutes of Health Stroke Scale data at index stroke, as well as modified Rankin Scale (mRS) at 3-6 months post-stroke were obtained from MRI-GENIE study of acute ischemic stroke (AIS) patients. Individual WMH volume was automatically derived from FLAIR-images. Stroke lesions were automatically segmented from DWI-images, spatially normalized and parcellated into atlas-defined brain regions. Stroke lesion effects on AIS severity and unfavorable outcomes (mRS>2) were modeled within a purpose-built machine learning and Bayesian regression framework. In particular, interaction effects between stroke lesions and a high versus low WMH burden were integrated via hierarchical model structures. Models were adjusted for the covariates age, age 2 , sex, total DWI-lesion and WMH volumes, and comorbidities. Data were split into derivation and validation cohorts. Results…

  92. 92
    top 2.7%

    Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults

    May A. Beydoun, Hind A. Beydoun, Marie Fanelli Kuczmarski, Jordan Weiss, Sharmin A Hossain and 3 more

    58 citationsOpen accessdoi:10.1212/wnl.0000000000200289OpenAlex

    Show abstract

    Background and Objectives Serum antioxidant vitamins and carotenoids may protect against neurodegeneration with age. We examined associations of these nutritional biomarkers with incident all-cause and Alzheimer disease (AD) dementia among US middle-aged and older adults. Methods Using data from the third National Health and Nutrition Examination Surveys (1988–1994), linked with Centers for Medicare & Medicaid follow-up data, we tested associations and interactions of serum vitamins A, C, and E and total and individual serum carotenoids and interactions with incident AD and all-cause dementia. Cox proportional hazards regression models were conducted. Results After ≤26 years follow-up (mean 16–17 years, 7,283 participants aged 45–90 years at baseline), serum lutein+zeaxanthin was associated with reduced risk of all-cause dementia (65+ age group), even in the lifestyle-adjusted model (per SD: hazard ratio [HR] 0.93, 95% CI 0.87–0.99; p = 0.037), but attenuated in comparison with a socioeconomic status (SES)–adjusted model (HR 0.92, 95% CI 0.86–0.93; p = 0.013). An inverse…

  93. 93
    top 2.8%

    Microembolism and Other Links Between Migraine and Stroke

    Simona Sacco, Andrea M. Harriott, Cenk Ayata, Raffaele Ornello, Rodrigo Bagur and 2 more

    57 citationsOpen accessdoi:10.1212/wnl.0000000000201699OpenAlex

    Show abstract

    Migraine and stroke are highly prevalent diseases with a high effect on quality of life, with multiple epidemiologic, pathophysiologic, clinical, and prognostic areas of overlap. Migraine is a risk factor for stroke. This risk is explained by common risk factors, migraine-specific mechanisms, and non-migraine-specific mechanisms that have a relevant role in patients with migraine with aura (e.g., atrial fibrillation and paradoxical embolism through a patent foramen ovale). Another important link between migraine aura and ischemic stroke is cardiac embolism. Cardioembolism is the most frequent cause of ischemic stroke, and increasing evidence suggests that microembolism, predominantly but not exclusively originating in the heart, is a contributing mechanism to the development of migraine aura. In this review, we discuss epidemiologic aspects of the association between migraine and ischemic stroke, the clinical presentation of ischemic strokes in patients with migraine, and the differentiation between migrainous and nonmigrainous infarctions. After that, we review migraine-specific…

  94. 94
    top 2.8%

    Association Between Net Water Uptake and Functional Outcome in Patients With Low ASPECTS Brain Lesions

    Gabriel Broocks, Lukas Meyer, Sarah S. Elsayed, Rosalie Victoria McDonough, Matthias Bechstein and 18 more

    57 citationsOpen accessdoi:10.1212/wnl.0000000000201601OpenAlex

    Show abstract

    Background and Objectives The effect of mechanical thrombectomy (MT) on functional outcome in patients with ischemic stroke with low ASPECTS is still uncertain. ASPECTS rating is based on the presence of ischemic hypoattenuation relative to normal; however, the degree of hypoattenuation, which directly reflects net uptake of water, is currently not considered an imaging biomarker in stroke triage. We hypothesized that the effect of thrombectomy on functional outcome in low ASPECTS patients depends on early lesion water uptake. Methods For this multicenter observational study, patients with anterior circulation stroke with ASPECTS ≤5 were consecutively analyzed. Net water uptake (NWU) was assessed as a quantitative imaging biomarker in admission CT. The primary end point was the rate of favorable functional outcome defined as modified Rankin Scale score 0–3 at day 90. The effect of recanalization on functional outcome was analyzed according to the degree of NWU within the early infarct lesion. Results A total of 254 patients were included, of which 148 (58%) underwent MT. The median…

  95. 95
    top 2.8%

    Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease

    Jian V. Huang, Bowen Su, Ville Karhunen, Dipender Gill, Verena Zuber and 16 more

    57 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000201489OpenAlex

    Show abstract

    Objectives: Whether chronic autoimmune inflammatory diseases causally affect the risk of AD is controversial. We characterised the relationship between inflammatory diseases and the risk of AD and explore the role of circulating inflammatory biomarkers in the relationships between inflammatory diseases and AD. Methods: We performed observational analyses for chronic autoimmune inflammatory diseases and risk of AD using data from 2,047,513 participants identified in the UK Clinical Practice Research Datalink (CPRD). Using data of a total of more than 1,100,000 individuals from 15 large scale genome-wide association study (GWAS) datasets, we performed two-sample Mendelian randomisation (MR) to investigate the relationships between chronic autoimmune inflammatory diseases, circulating inflammatory biomarker levels, and risk of AD. Results: Cox regression models using CPRD data showed that overall incidence of AD was higher among patients with inflammatory bowel disease (IBD) (hazard ratio (HR)=1.17; 95%CI 1.15 to 1.19; P-value=2.1×10-4), other inflammatory polyarthropathies &…

  96. 96
    top 2.8%

    Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy

    Andres Miguel Kanner, Anita Seixas Dias Saporta, Dong Kim, John J. Barry, Hamada Hamid Altalib and 25 more

    56 citationsOpen access (OTHER-OA)doi:10.1212/wnl.0000000000201671OpenAlex

    Show abstract

    Rationale and aim of the study: Mood, anxiety disorders and suicidality are more frequent in people with epilepsy than in the general population. Yet, their prevalence and the types of mood and anxiety disorders associated with suicidality at the time of the epilepsy diagnosis is not established. We sought to answer these questions in patients with newly diagnosed focal epilepsy and to assess their association with suicidal ideation and attempts. Methods: The data were derived from the Human Epilepsy Project study. A total of 347 consecutive adults aged 18 to 60 years old with newly diagnosed focal epilepsy were enrolled within 4 months of starting treatment. The types of mood and anxiety disorders were identified with the MINI International Neuropsychiatric Interview, while suicidal ideation (lifetime, current, active and passive) and suicidal attempts (lifetime, current) were established with the Columbia Suicidality Severity Rating Scale (CSSRS). Statistical analyses included T-test, Chi-square statistics and logistic regression analyses. Results: A total of 151 (43.5%) subjects…

  97. 97
    top 2.9%

    Blood Neurofilament Light in Progressive Multiple Sclerosis

    David Leppert, Harald Kropshofer, Dieter Adrian Häring, Frank Dahlke, Ashwini Patil and 4 more

    56 citationsOpen access (CC-BY-NC-ND)doi:10.1212/wnl.0000000000200258OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple sclerosis (PMS) with and without acute disease activity. METHODS: A post hoc blinded analysis of pNfL levels in 2 placebo-controlled, phase 3 studies in secondary progressive multiple sclerosis (SPMS; EXPAND) and primary progressive multiple sclerosis (PPMS; INFORMS) using siponimod and fingolimod, respectively, as active compounds was performed. pNfL levels were quantified using a single molecule array (Homebrew Simoa) immunoassay from stored ethylenediaminetetraacetic acid (EDTA) plasma samples of all patients who consented for exploratory biomarker analysis in either study; pNfL levels were divided into high (≥30 pg/mL) and low (<30 pg/mL) at baseline. We investigated the association of pNfL levels with disability progression, cognitive decline, and brain atrophy and their sensitivity to indicate treatment response through clinical measures. RESULTS: < 0.05). Independent of treatment, high vs low baseline…

  98. 98
    top 2.9%

    Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition

    Pontus Tideman, Erik Stomrud, Antoine Leuzy, Niklas Mattsson, Sebastian Palmqvist and 2 more

    55 citationsOpen access (CC-BY)doi:10.1212/wnl.0000000000013299OpenAlex

    Show abstract

    Background and ObjectivesThe neuropathologic changes underlying Alzheimer disease (AD) start before overt cognitive symptoms arise, but it is not well-known how they relate to the first subtle cognitive changes. The objective for this study was to examine the independent associations of the AD hallmarks β-amyloid (Aβ), tau, and neurodegeneration with different cognitive domains in cognitively unimpaired (CU) individuals. MethodsIn this cross-sectional study, CU participants from the prospective BioFINDER-2 study were included. All had CSF biomarkers (Aβ42 and phosphorylated tau [p-tau]181), MRI (cortical thickness of AD-susceptible regions), Aβ-PET (neocortical uptake), tau-PET (entorhinal uptake), and cognitive test data for memory, executive function, verbal function, and visuospatial function. Multivariable linear regression models were performed using either CSF Aβ42, p-tau181, and cortical thickness or Aβ-PET, tau-PET, and cortical thickness as predictors of cognitive function. The results were validated in an independent cohort (Alzheimer’s Disease Neuroimaging Initiative…

  99. 99
    top 2.9%

    Association of Dietary Intake of Flavonols With Changes in Global Cognition and Several Cognitive Abilities

    Thomas Monroe Holland, Puja Agarwal, Yamin Wang, Klodian Dhana, Sue E. Leurgans and 5 more

    54 citationsOpen accessdoi:10.1212/wnl.0000000000201541OpenAlex

    Show abstract

    BACKGROUND AND OBJECTIVES: Previous research has examined the association between cognition and flavonoids: bioactives found in foods, known to possess anti-inflammatory and antioxidant properties. We extend this research by investigating associations of dietary intakes of total flavonols and constituents (kaempferol, quercetin, myricetin, and isorhamnetin) on the change in cognitive performance in global cognition, episodic memory, semantic memory, visuospatial ability, perceptual speed, and working memory. METHODS: The study was conducted using 961 participants (aged 60-100 years) of the Rush Memory and Aging Project, a prospective cohort of community-dwelling Chicagoans who were followed for an average of 6.9 years. Diet was assessed using a validated semiquantitative food frequency questionnaire. Cognitive performance was assessed annually with a battery of 19 standardized tests. Flavonol intake was analyzed as a continuous variable using linear mixed-effects models. Cognitive domain scores were regressed on baseline calorie-adjusted flavonol variables. RESULTS: , late-life…

  100. 100
    top 3%

    Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease

    Yi Zhang, Xiaoqin He, Chengjun Mo, Xiaoqian Liu, Jian Li and 6 more

    54 citationsdoi:10.1212/wnl.0000000000201204OpenAlex

    Show abstract

    Background and Objectives Interindividual variability in levodopa efficacy is a challenge for the personalized treatment of Parkinson disease (PD). Gut microbiota might represent a new approach for personalized medicine. Recently, a novel microbial levodopa metabolism pathway was identified, which is mediated by tyrosine decarboxylase mainly encoded by tyrosine decarboxylase gene (tyrDC) in Enterococcus faecalis. In this study, we aimed to identify whether the abundance of microbial tyrDC gene and E faecalis is associated with levodopa responsiveness and could predict the drug response. Methods This cross-sectional study enrolled patients with PD between December 2019 and January 2022 and evaluated levodopa responsiveness using a levodopa challenge test. Patients were stratified into moderate and good responders based on levodopa responsiveness. The tyrDC gene and E. faecalis abundance in fecal samples were measured using quantitative real-time PCR. Plasma levodopa concentrations were measured using liquid chromatography-tandem mass spectrometry analysis. The predictive models for…

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to Neurology with publication year 2022, excluding retracted works and paratext such as editorials and errata. The top 100 by citation count are listed; the percentile is the rank divided by the cohort size. 100 of the 100 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.